[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 134
1. Kang SM, Kang HJ, Shin JH, Kim H, Shin DH, Kim SK, Kim JH, Chung KY, Kim SK, Chang J: Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer; 2007 Feb 1;109(3):581-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung.
  • BACKGROUND: Adenosquamous carcinoma of the lung is composed of adenocarcinomatous and squamous cell carcinomatous components.
  • The epidermal growth factor receptor (EGFR) mutations occur mostly in adenocarcinomas and rarely in squamous cell carcinoma of lung.
  • Attempts to investigate the EGFR mutation status in each component of adenosquamous carcinoma and to characterize the patients according to mutation status may help to understand the histogenesis of adenosquamous carcinoma.
  • METHODS: The mutation status of EGFR kinase domain from exon 18 to 21 was investigated in 25 Korean patients with adenosquamous carcinoma by polymerase chain reaction-single strand conformation polymorphism using the tissues of each component from the adenosquamous carcinoma tumor.
  • Identical EGFR mutations in both components of adenosquamous carcinoma were confirmed by nucleotide sequencing.
  • CONCLUSIONS: The frequency of EGFR mutation and clinicopathologic characteristics of the EGFR mutants in adenosquamous carcinoma are similar to those of Asian patients with adenocarcinomas.
  • Identical EGFR mutations in both components suggest the possibility of monoclonality in the histogenesis of adenosquamous carcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Adenosquamous / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Lung Neoplasms / genetics. Mutation / genetics. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17186532.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


2. Li B, Li Z, Zhang Y, Li Y, Wu W: [Clinical analysis of surgically treated patients with adenosquamous carcinoma of the lung]. Zhongguo Fei Ai Za Zhi; 2006 Oct 20;9(5):469-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of surgically treated patients with adenosquamous carcinoma of the lung].
  • BACKGROUND: Adenosquamous carcinoma of the lung is a rare pathologic type of lung cancer.
  • The aim of this study is to explore the clinical features of adenosquamous carcinoma of the lung.
  • METHODS: A total of 115 patients with adenosquamous carcinoma of the lung were retrospectively analysed, who were diagnosed by operation and pathology.
  • There were 14 patients (12.17%) without any symptom and 16 patients had residual carcinoma at the resection margin (14.04%).
  • CONCLUSIONS: The incidence of adenosquamous carcinoma of the lung in young women (under 49 years, especially under 39 years) is rather high.
  • The residual carcinoma at the resection margin often occurs after routine operation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176475.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Uramoto H, Yamada S, Hanagiri T: Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer. J Cardiothorac Surg; 2010;5:92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer.
  • BACKGROUND: adenosquamous carcinoma (ADSQ) of non-small cell lung cancer (NSCLC) is a rare disease and the biological behavior and clinicopathological characteristics have not yet been thoroughly described.
  • METHOD: This study reviewed the patient charts of 11 (1.6%) ADSQ cases among 779 patients with primary lung cancer who underwent a lung resection.
  • Five patients had coexistent double cancer including 2 gastric, 1 rectal, 1 prostate and 1 bladder cancer.
  • ADSQ was found less frequently in males than squamous cell carcinoma (SQ).
  • ADSQ was found more frequently in older patients, with advanced stage, advanced T status, and lymph node metastases than adenocarcinoma (AD).
  • The proportion with coexistent double cancer of AD, SQ, and ADSQ were 21.1, 17.6, and 45.5%, respectively.
  • ADSQ had a significantly correlation with double cancer (ADSQ vs. non- ADSQ p = 0.03).
  • A multivariate analysis showed no significant prognostic difference between the patients with ADSQ and non- ADSQ.
  • CONCLUSIONS: In this study, cases with ADSQ showed no significantly prognostic difference in comparison to AD and SQ.
  • However, surgeons must be cautious of any coexistent double cancer because approximately half of all patients with ADSQ of the lung have double cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1996 Apr;109(4):989-94 [8635382.001]
  • [Cites] Cancer Invest. 1993;11(6):641-51 [8221196.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):861-5 [9625833.001]
  • [Cites] Scand Cardiovasc J. 1999;33(1):29-32 [10093856.001]
  • [Cites] Respir Med. 2006 Dec;100(12):2073-84 [17056245.001]
  • [Cites] Ann Thorac Surg. 2007 Aug;84(2):702-7 [17643676.001]
  • [Cites] Med Oncol. 2009;26(1):27-31 [18483884.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1289-98 [10751354.001]
  • [Cites] Jpn J Cancer Res. 1999 Nov;90(11):1244-7 [10622536.001]
  • [Cites] Chest. 2000 Feb;117(2):374-9 [10669677.001]
  • [Cites] Ann Thorac Surg. 2003 Jun;75(6):1740-4 [12822609.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:219-42 [4088299.001]
  • [Cites] Ann Thorac Surg. 1987 Nov;44(5):462-6 [3675050.001]
  • [Cites] Am Rev Respir Dis. 1990 Jul;142(1):19-23 [2368969.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):649-54 [1985759.001]
  • [Cites] Am J Clin Pathol. 1992 May;97(5):678-85 [1575214.001]
  • [Cites] Ann Thorac Surg. 1993 Mar;55(3):593-6 [8452418.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • (PMID = 21034441.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit
  • [Other-IDs] NLM/ PMC2987925
  •  go-up   go-down


Advertisement
4. Sousa M, Cavadas S, Moreira MJ, Mellidez JC: Erlotinib in non-small cell lung cancer's second line treatment. Clinical case. Rev Port Pneumol; 2008 Oct;14 Suppl 3:S79-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib in non-small cell lung cancer's second line treatment. Clinical case.
  • [Transliterated title] Erlotinib no tratamento de segunda linha do cancro do pulmão de não pequenas células. Caso clínico.
  • Male, of 58 years, caucasian, construction worker, non smoker, with depressive syndrome, biliary lithiasis, renal cysts, surgery for benign intestinal polyps and relevant familiar history - aunt with lung cancer and mother with colon cancer.
  • He initiated thorax pain and vomitting and made a chest x-ray, showing a right basal lung mass.
  • During the etiologic study, he was submitted to thoracotomy with biopsy, in April 2006 - "fine granulations, spread for all the pulmonary field", allowing the diagnosis - adenosquamous lung carcinoma, stage IV (16/05/2006).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 Sociedade Portuguesa de Pneumologia/SPP.
  • (PMID = 25967692.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Lung cancer / Neoplasia do pulmão / adenosquamous carcinoma / carboplatin / carboplatino / carcinoma adenoescamoso / erlotinib / vinorelbina / vinorelbine
  •  go-up   go-down


5. Yu JQ, Yang ZG, Austin JH, Guo YK, Zhang SF: Adenosquamous carcinoma of the lung: CT-pathological correlation. Clin Radiol; 2005 Mar;60(3):364-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the lung: CT-pathological correlation.
  • AIM: To correlate CT morphological features and histopathological findings of adenosquamous carcinoma of the lung.
  • MATERIALS AND METHODS: In all, 29 patients underwent contrast-enhanced CT of an adenosquamous carcinoma of the lung, followed by resection of the cancer.
  • These CT features corresponded mainly to solid tumour growth, which was composed of both squamous cell carcinomatous and adenocarcinomatous tissue.
  • CONCLUSION: Adenosquamous carcinoma of the lung is shown to be characteristically a solid, lobulated nodule or mass, more commonly peripheral than central.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15710140.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Ohtsuka K, Ohnishi H, Fujiwara M, Kishino T, Matsushima S, Furuyashiki G, Takei H, Koshiishi Y, Goya T, Watanabe T: Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer; 2007 Feb 15;109(4):741-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
  • BACKGROUND: Tyrosine kinase domain (TKD) gene mutations of the epidermal growth factor receptor gene (EGFR) have proven to be clinically significant in nonsmall-cell lung cancer (NSCLC), particularly in adenocarcinoma.
  • However, TKD mutations together with deletion mutations in the extracellular domain of EGFR (EGFRvIII) have not been fully investigated in NSCLC except for adenocarcinoma.
  • METHODS: EGFR TKD mutations were investigated using direct sequencing and mutation-specific polymerase chain reaction (PCR), and EGFRvIII mutations were examined using reverse transcriptase-PCR in samples from 42 NSCLC patients and 6 NSCLC cell lines excluding adenocarcinoma.
  • RESULTS: EGFR TKD mutations were detected in 1 of 7 (14%) squamous-cell carcinomas with an adenocarcinoma component and 2 of 4 (50%) adenosquamous carcinomas.
  • In contrast, EGFR TKD mutations were not identified in 24 pure squamous-cell carcinomas without any adenocarcinoma component, 7 large-cell carcinomas, or 6 cell lines.
  • EGFRvIII was detected solely in 1 of 7 large-cell carcinomas (14%), but not in 31 squamous-cell carcinomas, 4 adenosquamous carcinomas, or 6 cell lines.
  • CONCLUSIONS: These results suggest that EGFR TKD mutations are found in NSCLCs with an adenocarcinoma element.
  • [MeSH-major] Carcinoma, Adenosquamous / genetics. Carcinoma, Large Cell / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA Mutational Analysis. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Male. Middle Aged. Neoplasm Staging. Prognosis. Protein Structure, Tertiary. Protein-Tyrosine Kinases / chemistry. Survival Rate

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17238183.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / epidermal growth factor receptor VIII; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


7. Fernando HC, Santos RS, Benfield JR, Grannis FW, Keenan RJ, Luketich JD, Close JM, Landreneau RJ: Lobar and sublobar resection with and without brachytherapy for small stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg; 2005 Feb;129(2):261-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobar and sublobar resection with and without brachytherapy for small stage IA non-small cell lung cancer.
  • OBJECTIVE: Computed tomographic screening is detecting ever smaller peripheral non-small cell lung cancers.
  • This study compared sublobar resection with lobar resection for stage IA non-small cell lung cancers to assess whether sublobar resection is appropriate treatment for certain lesions.
  • Our experience supports the further investigation of the use of sublobar resection with brachytherapy for peripheral stage IA non-small cell lung cancers smaller than 2 cm.
  • [MeSH-major] Brachytherapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Aged. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15678034.001).
  • [ISSN] 0022-5223
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


8. Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Bronson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG, Solca F, Wistuba II, Wong KK: HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A; 2009 Jan 13;106(2):474-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
  • Mutations in the HER2 kinase domain have been identified in human clinical lung cancer specimens.
  • Here we demonstrate that inducible expression of the most common HER2 mutant (HER2(YVMA)) in mouse lung epithelium causes invasive adenosquamous carcinomas restricted to proximal and distal bronchioles.
  • Continuous expression of HER2(YVMA) is essential for tumor maintenance, suggesting a key role for HER2 in lung adenosquamous tumorigenesis.
  • Immunohistochemical analysis of lung tumors treated with BIBW2992 and rapamycin combination revealed decreased phosphorylation levels for proteins in both upstream and downstream arms of MAPK and Akt/mTOR signaling axes, indicating inhibition of these pathways.
  • Based on these findings, clinical testing of the BIBW2992/rapamycin combination in non-small cell lung cancer patients with tumors expressing HER2 mutations is warranted.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2004 Sep 30;431(7008):525-6 [15457249.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1 Suppl 1):75-82 [14981584.001]
  • [Cites] Cell. 1989 Jul 28;58(2):287-92 [2568888.001]
  • [Cites] Oncogene. 1991 Jul;6(7):1189-94 [1713661.001]
  • [Cites] AJR Am J Roentgenol. 1994 Aug;163(2):301-6 [8037019.001]
  • [Cites] EMBO J. 1997 Apr 1;16(7):1647-55 [9130710.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1642-6 [15753357.001]
  • [Cites] Cancer. 2005 May 1;103(9):1865-73 [15770690.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):485-95 [16730237.001]
  • [Cites] Cancer Cell. 2006 Jul;10(1):25-38 [16843263.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4372s-4376s [16857813.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7242-51 [17189395.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):81-93 [17613438.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5023-7 [17311002.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4702-11 [18408761.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] EMBO J. 2001 Apr 2;20(7):1726-38 [11285236.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3249-62 [11751631.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 4):59-65 [11894015.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):495-505 [12620236.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):19-27 [14679114.001]
  • [Cites] Trends Mol Med. 2004 Oct;10(10):481-6 [15464447.001]
  • (PMID = 19122144.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / R01 CA122794; United States / NCI NIH HHS / CA / P20 CA90578; United States / NCI NIH HHS / CA / R01 CA90687; United States / NIA NIH HHS / AG / R01 AG2400401; United States / NCI NIH HHS / CA / R01 CA090687
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIBW 2992; 0 / Quinazolines; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC2626727
  •  go-up   go-down


9. Damadoğlu E, Aybatli A, Yalçinsoy M, Tahaoğlu C, Atasalihi A, Akkaya E, Yilmaz A: [Adenosquamous carcinoma of the lung (an analysis of 13 cases)]. Tuberk Toraks; 2005;53(2):161-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenosquamous carcinoma of the lung (an analysis of 13 cases)].
  • Adenosquamous carcinoma of the lung is a rare disease.
  • In this study, we retrospectively evaluated 13 patients with adenosquamous carcinoma of the lung diagnosed at our center between January 2001 and May 2004.
  • Preoperative pathological diagnosis was squamous cell carcinoma in eight patients, non-small cell lung carcinoma in four patients and adenocarcinoma in one patient.
  • [MeSH-major] Carcinoma, Adenosquamous / epidemiology. Lung Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100653.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


10. Li J, Zhang DC, He J, Liu XY, Mu JW, Zhang LZ: [The rule of lymph node metastasis of adenosquamous carcinoma of the lung]. Zhonghua Zhong Liu Za Zhi; 2009 Jul;31(7):524-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The rule of lymph node metastasis of adenosquamous carcinoma of the lung].
  • OBJECTIVE: To investigate the rule of lymph node metastasis of adenosquamous carcinoma of the lung.
  • METHODS: The data of 361 surgically treated patients with adenosquamous carcinoma of the lung from October 1965 to June 2003 were collected and retrospectively reviewed.
  • The skip mediastinal lymph node metastasis but N1 negative most commonly metastasized to station 7, then to station 4 from the tumor in the right lung and 5 from the tumor in the left lung.
  • CONCLUSION: The lung cancer growing in a different location has a different route and skipping metastasis to mediastinal lymph nodes.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lung Neoplasms / pathology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950701.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Sasaki H, Endo K, Yukiue H, Kobayashi Y, Yano M, Fujii Y: Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. Lung Cancer; 2007 Jan;55(1):129-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung.
  • We have investigated 26 adenosquamous lung cancer tissues and found that four EGFR mutations were mainly in female and non-smoker lung cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lung Cancer. 2006 Apr;52(1):47-52 [16503085.001]
  • (PMID = 17156891.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comment; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


12. Diaz A, Batista AE, Montero E: Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor. J Interferon Cytokine Res; 2009 Aug;29(8):433-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor.
  • Interferon-alpha (IFN-alpha) induces growth inhibition but also may up-regulate the EGFR expression in some cancer cell lines.
  • We aimed to determine whether the IFN-alpha combined with an EGFR-specific monoclonal antibody (nimotuzumab) may affect the growth of human tumor epithelial cell lines with different EGFR expression levels.
  • H125, a lung adenosquamous carcinoma, and A431, a vulvar epidermoid carcinoma, cell lines express intermediate and high levels of EGFR, respectively, whereas MDA MB231, a breast adenocarcinoma cell line expresses undetectable levels of EGFR measured by flow cytometry/FACS.
  • We found that IFN-alpha alone inhibited in a dose-dependent fashion the growth of all cell lines, but only up-regulated the EGFR expression in the lung carcinoma-derived cell line.
  • Noteworthy, the combined treatment did not modify the complement-mediated cytotoxicity of the antibody although the antiproliferative activity of nimotuzumab in H125 cells in vitro increased when an IFN-alpha-conditioning treatment was used.
  • In conclusion, this study may provide insights about the rational use of EGFR inhibitors into the immunopharmacological management of targeted therapies including the IFN-alpha for lung cancer.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Epithelial Cells / immunology. Growth Inhibitors / metabolism. Immunologic Factors / pharmacology. Immunotherapy. Interferon-alpha / metabolism. Lung Neoplasms / immunology. Lung Neoplasms / therapy. Receptor, Epidermal Growth Factor / immunology
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Breast Neoplasms / immunology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Cell Growth Processes / drug effects. Cell Line, Tumor. Cell Separation. Complement System Proteins / metabolism. Cytotoxicity, Immunologic / drug effects. Dose-Response Relationship, Immunologic. Drug Synergism. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. Vulvar Neoplasms / immunology. Vulvar Neoplasms / metabolism. Vulvar Neoplasms / pathology. Vulvar Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514842.001).
  • [ISSN] 1557-7465
  • [Journal-full-title] Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • [ISO-abbreviation] J. Interferon Cytokine Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Growth Inhibitors; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / nimotuzumab; 9007-36-7 / Complement System Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


13. Morinaga R, Matsunaga N, Iwata A, Kishi K, Tokimatsu I, Nagai H, Kadota J: [A case of diaphragmatic paralysis caused by herpes zoster after anticancer chemotherapy]. Nihon Kokyuki Gakkai Zasshi; 2007 Feb;45(2):166-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 61-year-old woman who had been followed up after resection of lung cancer (adenosquamous cell carcinoma), was admitted to our hospital because of recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Herpes Zoster / chemically induced. Herpes Zoster / complications. Respiratory Paralysis / etiology
  • [MeSH-minor] Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / surgery. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Lymph Node Excision. Middle Aged. Pneumonectomy. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - paralysis.
  • MedlinePlus Health Information. consumer health - Shingles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352174.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


14. Sugio K, Nagashima A, Nakanishi R, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Takenoyama M, Hanagiri T, Yasumoto K: Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC).
  • This phase II trial assessed the feasibility, safety and efficacy of a bi-weekly schedule for adjuvant chemotherapy.
  • The patients were stratified by gender, histology (adenoca vs. non-adenoca) and disease stage.
  • The histologic types included adenocarcinoma (n=51), squamous cell carcinoma (n=18), large cell carcinoma (n=5), and adenosquamous cell carcinoma (n=1).
  • Twenty-one of 39 pts (54%) in arm A and 25 of 36 pts (69%) in arm B completed 8 cycles, and 59% in arm A and 81% in arm B completed ≥6 cycles.
  • Up to 12/2008, 11 of 39 pts in arm A and 13 of 36 pts in arm B had recurrent disease, but no significant difference was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963358.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Begum M, Robinson L, Sommers E, Bepler G: The impact of PET-based staging on survival of patients with stage I lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):7570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of PET-based staging on survival of patients with stage I lung cancer.
  • : 7570 Background: Patients with completely resected stage I lung cancer have the best survival.
  • Stage I, as defined by Mountain in 1997, includes tumors of any size located within one lobe of the lung without involvement of the parietal pleura, a distance of 2 cm or more from the carina, and no evidence for metastatic disease in any pulmonary, hilar, or mediastinal lymph node or distant site.
  • METHODS: To test this hypothesis, we compiled a database of all patients with stage I lung cancer that underwent a complete surgical resection at the Moffitt Cancer Center from 1996 to 2006.
  • Description of pts: 638 women, 592 men; 11 African-American, 1215 Caucasian; 18 Hispanic, 1202 Non-Hispanic; age range 28.1-94.0 y, mean 68.9 y, median 69.9 y; 26 pneumonectomies, 243 segmentectomies or wedge resections; 699 adeno-, 15 adenosquamous, 325 squamous, 25 large cell, 57 neuroendocrine carcinomas; maximum tumor diameter range 0.1-25 cm, mean 2.9 cm, median 2.3 cm; 477 dead (survival 0.0-138.8 months), 753 alive (survival 0.1-144.4 months).
  • CONCLUSIONS: We conclude that the introduction of PET scanning has not impacted on the survival of patients with stage I lung cancer at our institution.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963355.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Uramoto H, Yamada S, Hanagiri T: Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung. Anticancer Res; 2010 Nov;30(11):4717-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung.
  • The aim of this study was to detect the deltaNp63 expression in the squamous carcinoma component of adenosquamous carcinoma and evaluate its usefulness as a specific squamous carcinoma marker.
  • PATIENTS AND METHODS: Immunohistochemistry was used to analyze the protein expression of deltaNp63 and high molecular weight cytokeratin in paraffin-embedded tumor samples from 17 patients with well-characterized adenosquamous carcinoma.
  • It was easy to discriminate the squamous carcinoma and adenocarcinoma components in all tumors.
  • CONCLUSION: These findings indicated that the deltaNp63 status was useful for distinguishing squamous carcinoma from adenocarcinoma in formalin-postfixed adenosquamous carcinoma specimens.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Adenosquamous / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115930.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


17. Satoh M, Wakabayashi O, Araya Y, Jinushi E, Yoshida F: [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor]. Nihon Kokyuki Gakkai Zasshi; 2009 Sep;47(9):798-804
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor].
  • Chest X-ray revealed multiple emphysematous bullae in both lungs and a tumor shadow in the right upper lobe.
  • The tumor was diagnosed as a non-small-cell lung cancer with direct invasion to the adjacent rib.
  • Autopsy revealed multiple emphysematous bullae, poorly differentiated adenosquamous cell carcinoma of the lung, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor.
  • This case suggests the possibility that von Recklinghausen's disease associated with emphysematous bullae is a risk factor for lung cancer.
  • Although von Recklinghausen's disease is reportedly associated with various malignant tumors, it is quite rare for von Recklinghausen's disease to be associated with triple non-neurogenic tumors.
  • [MeSH-major] Autopsy. Carcinoid Tumor / etiology. Carcinoma, Adenosquamous / etiology. Duodenal Neoplasms / etiology. Gastrointestinal Stromal Tumors / etiology. Lung Neoplasms / etiology. Neoplasms, Multiple Primary. Neurofibromatosis 1 / complications
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Pulmonary Emphysema / complications. Pulmonary Emphysema / diagnosis. Pulmonary Emphysema / pathology. Risk Factors

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827584.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


18. Bastide K, Ugolin N, Levalois C, Bernaudin JF, Chevillard S: Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level? Lung Cancer; 2010 Apr;68(1):1-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level?
  • Adenocarcinomas (AC), squamous cell carcinomas (SCC) and adenosquamous carcinomas (ASC) are three histological subtypes of non-small-cell lung carcinomas (NSCLC).
  • ASC are morphologically mixed tumours that contain the two cell components AC and SCC.
  • In conclusion, the ASC mixed lung tumours are more complex than simple mixes of AC and SCC components.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Adenosquamous / genetics. Carcinoma, Squamous Cell / genetics. Lung / metabolism. Lung Neoplasms / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Transformation, Neoplastic. DNA Mutational Analysis. GATA6 Transcription Factor / genetics. GATA6 Transcription Factor / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, ras / genetics. MAP Kinase Signaling System / genetics. Microarray Analysis. Mucin-1 / genetics. Mucin-1 / metabolism. Radon / toxicity. Rats. Rats, Sprague-Dawley. Receptor, Notch2 / genetics. Receptor, Notch2 / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. RADON, RADIOACTIVE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20004040.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / GATA6 Transcription Factor; 0 / Gata6 protein, rat; 0 / Mucin-1; 0 / Receptor, Notch2; Q74S4N8N1G / Radon
  • [Number-of-references] 61
  •  go-up   go-down


19. Kobashi Y, Mouri K, Fukuda M, Yoshida K, Miyashita N, Niki Y, Nakata M, Mikio O: [A case of pulmonary adenosquamous cell carcinoma with thin-wall cavities]. Nihon Kokyuki Gakkai Zasshi; 2005 Jan;43(1):59-62
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pulmonary adenosquamous cell carcinoma with thin-wall cavities].
  • A 68-year-old man was admitted to our hospital because of continuous cough of three months duration and for investigation of a thin-wall cavitary lesion (> 3 cm) in the right upper lung field.
  • A histological diagnosis of pulmonary adenocarcinoma was obtained by bronchoscopic examination, and he was transferred to the Department of Thoracic Surgery where a right upper lobectomy was performed.
  • Most of the surrounding cavity consisted of the components of a well differentiated squamous cell carcinoma with keratinization and slightly different components of a poorly differentiated adenocarcinoma with mucous production.
  • The final diagnosis was pulmonary adenosquamous cell carcinoma and the postoperative histological classification was T2N2M0 (Stage 3A) because of metastasis to the lymph nodes (#4 and #11).
  • Although squamous cell carcinoma has been reported to be the histological type, tending to form thin-wall cavities among patients with lung cancer reported to be squamous cell carcinoma, recently an increasing number of such cavities have been reported among patients with pulmonary adenocarcinoma.
  • Herein, we have reported a rare case of histological diagnosis of pulmonary adenosquamous cell carcinoma with cavity formation.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lung / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15704455.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Lee JW, Soung YH, Kim SY, Nam SW, Park WS, Wang YP, Jo KH, Moon SW, Song SY, Lee JY, Yoo NJ, Lee SH: ERBB2 kinase domain mutation in the lung squamous cell carcinoma. Cancer Lett; 2006 Jun 8;237(1):89-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
  • Recent reports revealed that the kinase domain of ERBB2 gene, a proto-oncogene, is somatically mutated in the lung adenocarcinomas, suggesting the mutated ERBB2 gene may act as an oncogene in human cancers.
  • The purpose of this was to see whether the ERBB2 kinase domain is mutated in other lung cancer types besides the adenocarcinoma.
  • Here, we performed mutational analysis of the ERBB2 kinase domain by polymerase chain reaction-single strand conformation polymorphism assay in 114 non-adenocarcinoma type non-small cell lung cancers (NSCLCs) tissue samples, including 100 squamous cell carcinomas, three adenosquamous carcinomas and 11 large cell carcinomas.
  • We detected the ERBB2 kinase domain mutation in one squamous cell carcinoma (1.0%).
  • We simultaneously analyzed the somatic mutations of EGFR, K-RAS, PIK3CA and BRAF genes in the squamous cell carcinoma with the ERBB2 mutation, and found that the tumor did not harbor any EGFR or ERBB2 or K-RAS or PIK3CA or BRAF gene mutation, either.
  • This study demonstrated that in addition to lung adenocarcinoma ERBB2 kinase domain mutation could occur in lung squamous cell carcinomas, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations may occasionally contribute to the development of lung squamous cell carcinomas.
  • [MeSH-major] Carcinoma, Adenosquamous / genetics. Carcinoma, Large Cell / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Receptor, ErbB-2 / genetics


21. Okano T, Gemma A, Hosoya Y, Hosomi Y, Nara M, Kokubo Y, Yoshimura A, Shibuya M, Nagashima M, Harris CC, Kudoh S: Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Oncol Rep; 2006 Mar;15(3):545-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
  • The ING1 gene is involved in the regulation of the cell cycle, senescence, and apoptosis and is a novel candidate tumor suppressor gene.
  • To determine whether an alteration in these genes plays a role in carcinogenesis and tumor progression in lung cancer, we screened 30 human lung cancer cell lines and 31 primary lung cancer tumors for mutations in these genes using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing.
  • We also examined the expression of ING1 and ING2 in lung cancer cell lines that either had or lacked a p53 mutation, and in a control bronchial epithelium cell line, using quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR).
  • ING1 expression was up-regulated in all 7 lung cancer cell lines that had a p53 mutation, while the expression of ING2 was down-regulated in 6 of 7 lung cancer cell lines that had a p53 mutation.
  • These results suggest that the ING1 and ING2 genes have different roles in lung carcinogenesis and progression, and the ING2 gene may be an independent tumor suppressor candidate on p53.
  • [MeSH-major] Lung Neoplasms / pathology. Mutation. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Base Sequence. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. DNA Mutational Analysis. DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Humans. Intracellular Signaling Peptides and Proteins / genetics. Nuclear Proteins / genetics. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Cytoplasmic and Nuclear / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465410.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Homeodomain Proteins; 0 / ING1 protein, human; 0 / ING2 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


22. Sugimoto Y, Semba H, Fujii S, Furukawa E, Kurano R: [Clinical analysis of primary lung cancer with a thin-walled cavity to explain the mechanism of thin-walled cavity formation]. Nihon Kokyuki Gakkai Zasshi; 2007 Jun;45(6):460-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of primary lung cancer with a thin-walled cavity to explain the mechanism of thin-walled cavity formation].
  • We report 8 rare cases of primary lung cancer which showed a thin-walled cavity on chest X-ray and CT.
  • We analyzed 8 cases (7 men, 1 woman) of primary lung cancer with thin-walled cavities admitted to our hospital between 1995 and 2006.
  • Histologically, there were 5 cases of adenocarcinoma, 2 of squamous cell carcinoma, and 1 of adenosquamous cell carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Squamous Cell / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17644941.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


23. Otrock ZK, Mahfouz RA, Salem ZM: Four primary tumors of lung, bladder, prostate, and breast in a male patient. South Med J; 2005 Sep;98(9):946-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four primary tumors of lung, bladder, prostate, and breast in a male patient.
  • Immunohistochemical stains showed tumor cell nuclei to be negative for p53 over-expression.
  • The tumors included an adenosquamous cell carcinoma of the lung, transitional cell carcinoma of the urinary bladder, and adenocarcinomas of the prostate and the breast.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma / complications. Lung Neoplasms / complications. Prostatic Neoplasms / complications. Urologic Neoplasms / complications
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystectomy. Fatal Outcome. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mastectomy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Radiotherapy, Adjuvant. Shock, Septic / complications. Spinal Neoplasms / complications. Spinal Neoplasms / diagnosis. Spinal Neoplasms / secondary. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217994.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Wang MZ, Li LY, Wang SL, Zhang XT, Zhong W, Zhang L, Li JR: [Evaluation of efficacy and safety of ZD1839 as monotherapy in Chinese patients with advanced non-small cell lung cancer]. Zhonghua Nei Ke Za Zhi; 2008 Apr;47(4):291-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of efficacy and safety of ZD1839 as monotherapy in Chinese patients with advanced non-small cell lung cancer].
  • OBJECTIVE: To report the outcome of gefitinib for Chinese patients with advanced nonsmall cell lung cancer(NSCLC) at Peking Union Medical College Hospital.
  • Thirty-two patients had squamous cell carcinoma, 125 adenocarcinoma, 30 bronchoalveolar carcinoma or adenocarcinoma with partial bronchoalveolar carcinoma, 6 adenosquamous carcinoma, and 11 unspecified.
  • Median survival was calculated using the Kaplan-Meier method and a Cox regression analysis was used to detect differences in median survival between strata.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843952.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


25. Spaggiari L, D' Aiuto M, Veronesi G, Pelosi G, de Pas T, Catalano G, de Braud F: Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer. Ann Thorac Surg; 2005 Jan;79(1):234-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer.
  • BACKGROUND: Extended pneumonectomy with partial resection of the left atrium for lung cancer is not frequently performed; therefore, its results remain controversial.
  • METHODS: From November 1996 to December 2003, 15 patients underwent extended pneumonectomy with partial resection of the left atrium for lung cancer, without cardiopulmonary bypass.
  • The T status was T4 in 10 patients, pT3 in 3 patients, and T0 in the remaining 2 patients.
  • The were 10 squamous cell carcinomas (60%), 2 adenocarcinomas, 1 adenosquamous carcinoma, 1 mucoepidermoid carcinoma, and 1 atypical carcinoid tumor.
  • CONCLUSIONS: Extended pneumonectomy with partial resection of the left atrium for advanced lung cancer is a feasible procedure, with low postoperative morbidity and mortality.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Heart Atria / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adult. Aged. Antineoplastic Agents / therapeutic use. Arrhythmias, Cardiac / epidemiology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Cardiopulmonary Bypass. Combined Modality Therapy. Databases, Factual. Female. Humans. Length of Stay / statistics & numerical data. Life Tables. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Complications / epidemiology. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620949.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 11
  •  go-up   go-down


26. Sasaki H, Okuda K, Takada M, Kawahara M, Kitahara N, Matsumura A, Iuchi K, Kawaguchi T, Kubo A, Endo K, Kawano O, Yukiue H, Yano M, Fujii Y: A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer. J Cancer Res Clin Oncol; 2008 Dec;134(12):1371-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer.
  • INTRODUCTION: Mutations of the epidermal growth factor receptor (EGFR) gene at kinase domain have been reported in non-small-cell lung cancer (NSCLC).
  • Two hundred and sixty-eight adenocarcinoma cases were included.
  • RESULTS: A novel EGFR somatic mutation at exon 25 (G3034, D1012H) was found from 1 of 398 lung cancer patients.
  • CONCLUSION: EGFR mutation at C-terminal in lung cancers seemed to be extremely rare, however, this D1012H mutation might be a role in EGFR function.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Exons / genetics. Lung Neoplasms / genetics. Polymorphism, Genetic / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Aged. Asian Continental Ancestry Group / genetics. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. DNA Primers. Female. Humans. Lung / metabolism. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Smoking. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacogenomics J. 2008 Apr;8(2):129-38 [17375033.001]
  • [Cites] J Biol Chem. 1996 Jan 5;271(1):311-8 [8550578.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Pharmacogenet Genomics. 2005 May;15(5):343-7 [15864136.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2924-9 [15837743.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):136-43 [14734462.001]
  • [Cites] J Biol Chem. 1985 Nov 25;260(27):14642-7 [2997217.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):375-84 [16199108.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15 [11597399.001]
  • [Cites] Structure. 2004 Dec;12(12):2265-75 [15576039.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jan;65(1):12-8 [16410744.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4142-7 [10463620.001]
  • [Cites] J Biol Chem. 1988 Mar 15;263(8):3610-7 [3346210.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):180-4 [16003726.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8919-23 [15604253.001]
  • [Cites] Protein Sci. 2006 May;15(5):1142-52 [16597832.001]
  • [Cites] J Thorac Oncol. 2006 Sep;1(7):635-47 [17409930.001]
  • [Cites] Exp Cell Res. 2007 Sep 10;313(15):3349-63 [17643422.001]
  • (PMID = 18478265.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


27. Feng X, Li L, Gao Y, Zhang J, Ying J, Xiao T, Gao J, Liu X, Sun Y, Cheng S: Fhit protein expression in lung cancer studied by high-throughput tissue microarray. Bull Cancer; 2007 Mar;94(3):E8-11
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fhit protein expression in lung cancer studied by high-throughput tissue microarray.
  • AIM: To study the expression of Fhit protein in lung cancers and its potential relevance in the diagnosis and prognosis of lung cancers.
  • METHODS: Tissue microarrays (TMA) and Immunohistochemistry (IHC) were performed in 321 cases of lung cancers.
  • RESULTS: In our TMA blocks comprising 321 cases of lung cancer, there were 253 (78.8 %) cases valid for Fhit protein assessment.
  • Fhit protein loss in NSCLCs (non-small cell lung carcinoma was significantly lower than in SCLCs (small cell lung cancers) (p < 0.05), in most squamous cell carcinomas (85 out of 105, 81.0 %), and in a smaller portion of adenocarcinomas (53 out of 109, 48.6 %; p < 0.05).
  • CONCLUSIONS: Our studies showed that the loss or reduced expression of Fhit, a tumour suppressor gene is a frequent occurrence in lung cancers, with variations amongst different histological subtypes.
  • [MeSH-major] Acid Anhydride Hydrolases / analysis. Biomarkers, Tumor / analysis. Lung Neoplasms / chemistry. Neoplasm Proteins / analysis. Tissue Array Analysis / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / chemistry. Carcinoma, Non-Small-Cell Lung / chemistry. Carcinoma, Small Cell / chemistry. Carcinoma, Squamous Cell / chemistry. Female. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Male. Middle Aged. Reagent Kits, Diagnostic

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17371765.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Reagent Kits, Diagnostic; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


28. Hu YY, Sun XR, Lin XP, Liang PY, Zhang X, Fan W: [Application of 18F-FDG PET/CT in cervical cancer with elevated levels of serum squamous cell carcinoma antigen during the follow-up]. Ai Zheng; 2009 Sep;28(9):994-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of 18F-FDG PET/CT in cervical cancer with elevated levels of serum squamous cell carcinoma antigen during the follow-up].
  • BACKGROUND AND OBJECTIVE: Accurate and early diagnosis of recurrence for cervical cancer after the treatment and aggressive salvage treatment could improve the prognosis of this disease.
  • Serum squamous cell carcinoma antigen (SCCAg) is the most commonly used tumor marker for the detection of asymptomatic recurrence of cervical cancer.
  • This study was to evaluate the application and value of (18)F-FDG PET/CT in cervical cancer with elevated of serum SCCAg level during the follow-up.
  • METHODS: Thirty-one patients with cervical cancer with elevated serum SCCAg level during the follow-up undergoing (18)F-FDG PET/CT in Sun Yat-sen University Cancer Center between August 2005 and November 2008 were entered into this retrospective study.
  • RESULTS: All 31 patients'pathological examination showed squamous cell carcinoma, including three adenosquamous carcinoma.
  • Of these 31 patients, three were confirmed to have local recurrent disease, 27 were verified to have metastatic disease and one was diagnosed as primary lung squamous cell carcinoma by pathological or clinical manifestations.
  • The total detection rate of PET/CT for malignancy was 100% (31/31); the diagnostic accuracy of PET/CT for recurrent cervical cancer was 96.8% (30/31).
  • CONCLUSIONS: An elevated level of SCCAg in cervical cancer during the follow-up indicates tumor recurrence.
  • [MeSH-major] Antigens, Neoplasm / blood. Carcinoma, Squamous Cell / radiography. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Serpins / blood. Uterine Cervical Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Carcinoma, Adenosquamous / blood. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Radiopharmaceuticals. Retrospective Studies. Tomography, X-Ray Computed


29. Balcer-Kubiczek EK, Attarpour M, Edelman MJ: The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines. Cancer Chemother Pharmacol; 2007 May;59(6):781-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines.
  • PURPOSE: The present study was designed to investigate the ability of N-[4-(5-bromo-2-pyrimidyloxy)-3-methylphenyl]-(dimemethylamino)-benzoylphenylurea (dimemethylamino benzoylphenylurea;.
  • BPU) to sensitize cells to radiation and to examine the relationship between phenotype versus survival, DNA damage, apoptosis, or cell cycle progression in non-small cell lung cancer (NSCLC) cell lines.
  • METHODS: Asynchronous cultures of three NSCLC (phenotype) lines, A549 (adenocarcinoma), NCI-H226 (squamous) and NCI-H596 (adenosquamous) were used.
  • Cells were treated for 24 h with BPU at various concentrations (0-10 microM) to obtain drug doses for inhibiting cell survival by approximately 50% (IC50).
  • Cell survival was determined by a colony-forming ability assay.
  • The effect of BPU on the cell cycle distribution and induction of apoptosis were measured by flow cytometry-based assays.
  • RESULTS: BPU (1.5 microM) for 24 h produced approximately 50% cell survival.
  • BPU and X-irradiation were synergistic in the three cell lines at survival levels of 20-50%.
  • Flow cytometry analysis of replicate experiments with BPU (1.5 microM for 24 h) showed that BPU blocked cell progression at S and/or G2/M.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Methylurea Compounds / therapeutic use
  • [MeSH-minor] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Survival / drug effects. Combined Modality Therapy. DNA Damage / drug effects. Humans. Radiation-Sensitizing Agents / therapeutic use. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16957930.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Methylurea Compounds; 0 / Radiation-Sensitizing Agents; 0 / dimethyl benzoylphenyl urea
  •  go-up   go-down


30. Tanaka T, Sekimura A, Tanaka H, Tonegawa K, Ogawa K, Haneda H: [Gallbladder metastasis of large cell lung cancer]. Kyobu Geka; 2009 Nov;62(12):1069-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gallbladder metastasis of large cell lung cancer].
  • A man, who received right upper lobectomy of the lung due to stage IIB large cell carcinoma 7 and half years ago, visited our hospital complaining of right upper abdominal pain.
  • Pathological diagnosis was adenosquamous cell carcinoma After 1 year and 4 months later, left adrenal gland tumor was found by CT scan, and the surgery was conducted.
  • Pathologically, it was diagnosed as metastasis from lung cancer.
  • By reevaluation of pathology of the gallbladder, the tumor was found to have similar component of resected lung cancer, suggesting the possibility of the tumor to be metastatic.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Gallbladder Neoplasms / secondary. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894573.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Iwanami T, Uramoto H, Baba T, Takenaka M, Yokoyama E, Oka S, So T, Ono K, So T, Takenoyama M, Hanagiri T, Iwata T, Inoue M, Yasumoto K: [Treatment recommendations for adrenal metastasis of non-small cell lung cancer]. Kyobu Geka; 2010 Dec;63(13):1101-6; discussion 1106-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment recommendations for adrenal metastasis of non-small cell lung cancer].
  • To evaluate the optimum treatment strategy for metastatic adrenal tumors derived from non-small cell lung cancer (NSCLC), we retrospectively analyzed 17 consecutive cases (8 resection cases: 4 synchronous and 4 metachronous: 9 non-resection cases: 3 synchronous and 6 metachronous) who received surgical resection for NSCLC.
  • Of these, 9, 3, 2, 2, and 1 patient (s) were diagnosed as having adenocarcinoma, squamous cell carcinoma, pleomorphic carcinoma, large cell carcinoma, and adenosquamous cell carcinoma, respectively.
  • The mean interval after lung resection and treatment of metachronous adrenal metastasis was 9.9 months.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


32. Mano H: Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci; 2008 Dec;99(12):2349-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
  • However, chromosome translocations involving the e26 transformation-specific sequence transcription factor loci have been demonstrated recently in many prostate cancer cases.
  • Furthermore, through a functional screening with retroviral cDNA expression libraries, we have discovered the fusion-type protein tyrosine kinase echinoderm microtubule-associated protein like-4 (EML4)-anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) specimens.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Neoplasms / genetics. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Carcinoma, Adenosquamous / genetics. Cell Transformation, Neoplastic. Chromosomes, Human, Pair 2. Exons. Gene Rearrangement. Humans. Male. Middle Aged. Models, Genetic. Translocation, Genetic

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032370.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion
  • [Number-of-references] 71
  •  go-up   go-down


33. Caldarella A, Crocetti E, Comin CE, Janni A, Pegna AL, Paci E: Gender differences in non-small cell lung cancer: a population-based study. Eur J Surg Oncol; 2007 Aug;33(6):763-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender differences in non-small cell lung cancer: a population-based study.
  • BACKGROUND: A retrospective study including all patients with non-small cell lung cancer carcinoma in a population-based registry was performed to characterize gender differences in lung cancer and to analyze the factors influencing prognosis in women.
  • METHODS: We retrieved through the Tuscan Cancer Registry (RTT) archive 2,523 lung tumor cases diagnosed during the period 1996-1998 in the provinces of Florence and Prato, central Italy.
  • We compared the prognosis within 464 non-small lung cancer women and 1,798 men in a population-based case series.
  • The influence of the following variables on postoperative survival were analyzed: age, cell type, pathologic T and N status, site of tumor and type of surgical resection.
  • RESULTS: The age at diagnosis was similar in women and in men.
  • Women were significantly more likely to have adenocarcinoma but less likely to have squamous cell carcinoma compared with men.
  • CONCLUSIONS: Lung cancer was more frequent in men than in women, but overall survival is similar.
  • Differences in lung cancer histology and rate of pneumonectomies were found between men and women.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / epidemiology. Lung Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Age Factors. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Female. Follow-Up Studies. Humans. Italy / epidemiology. Lymph Node Excision / statistics & numerical data. Male. Middle Aged. Neoplasm Staging. Pneumonectomy / statistics & numerical data. Population Surveillance. Prognosis. Registries. Retrospective Studies. Sex Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306497.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Brokx HA, Visser O, Postmus PE, Paul MA: Surgical treatment for octogenarians with lung cancer: results from a population-based series of 124 patients. J Thorac Oncol; 2007 Nov;2(11):1013-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for octogenarians with lung cancer: results from a population-based series of 124 patients.
  • INTRODUCTION: With the increasing life span in the Western world, the number of octogenarians with resectable, localized non-small cell lung cancer is increasing.
  • Previous reports on the outcome of surgery for lung cancer in octogenarians were mainly derived from single institutions.
  • METHODS: General data on all patients diagnosed with lung cancer in the period 1989 to 2004 were retrieved from the Amsterdam Cancer Registry.
  • Absolute and relative survival for octogenarians relative to other age groups and relative to other treatment modalities in octogenarians with clinical stage I/II lung cancer was performed.
  • RESULTS: Non-small cell lung cancer was diagnosed in 1993 octogenarians (14% of all lung cancer patients).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / epidemiology. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17975492.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


35. Tsukioka T, Nishiyama N, Iwata T, Izumi N, Mizuguchi S, Morita R, Inoue K, Suehiro S: Early recurrence of completely resected N2-positive non-small-cell lung cancer. Gen Thorac Cardiovasc Surg; 2007 Mar;55(3):113-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early recurrence of completely resected N2-positive non-small-cell lung cancer.
  • It is suggested that the number of N1 stations with metastasis is a risk factor for early recurrence and a poor prognostic factor in N2 disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Neoplasm Recurrence, Local. Pneumonectomy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Analysis of Variance. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17447509.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Satoh Y, Hoshi R, Ishikawa Y, Horai T, Okumura S, Nakagawa K: Recurrence patterns in patients with early stage non-small cell lung cancers undergoing positive pleural lavage cytology. Ann Thorac Surg; 2007 Jan;83(1):197-202
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence patterns in patients with early stage non-small cell lung cancers undergoing positive pleural lavage cytology.
  • BACKGROUND: Cytologic approaches such as pleural lavage cytology (PLC) are considered as possible aids to assessing prognosis of lung cancers.
  • However, there is some controversy whether radical surgery is warranted based on the positive PLC findings with stage I non-small cell lung cancers (NSCLCs).
  • METHODS: From January 1991 to December 2002, PLC was performed before any manipulation or resection of the lung for 853 consecutive patients who had no macroscopic pleural effusion, dissemination, or diffuse adhesions and who subsequently underwent curative resection for NSCLCs.
  • RESULTS: PLC findings were positive in 41 patients (4.8%), rates being most frequent with adenosquamous carcinomas and adenocarcinomas.
  • CONCLUSIONS: PLC is a distinct prognostic factor for early stage lung carcinomas.
  • Thus, we suggest that cytologic examination of PLC should be routine, even for patients with stage I NSCLCs before beginning lung resection.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Pleura / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2007 Jan;83(1):202-3 [17184662.001]
  • (PMID = 17184661.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


37. Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Fischedik K, Stanzel S, Breuer C, Skobel E, Asadpour B, Schmachtenberg A, Buell U, Eble MJ: Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study. Strahlenther Onkol; 2006 May;182(5):263-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study.
  • PURPOSE: To determine the maximum tolerated dose (MTD) of gemcitabine every 2 weeks to a concurrent radiotherapy administered during an aggressive program of sequential and simultaneous radio-/chemotherapy for locally advanced, unresectable non-small cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Ten patients with histologically confirmed NSCLC were observed and treated in accordance with a combined radio-/chemotherapy protocol.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Disease Progression. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Positron-Emission Tomography. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Remission Induction. Respiratory Function Tests. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16673059.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


38. Okwuosa TM, Williams KA: "Mass-ive" infarction: case report and review of myocardial metastatic malignancies. J Nucl Cardiol; 2008 Sep-Oct;15(5):719-26
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cardiac metastases from lung cancer are rarely diagnosed ante mortem and usually cause no symptoms or signs.
  • In this case report cardiac metastasis from a primary adenosquamous cancer of the lung presented as myocardial infarction in a 61-year-old man.
  • His diagnosis was made and confirmed via multimodality imaging of the heart, which is also reviewed in depth.
  • [MeSH-major] Heart Neoplasms / secondary. Lung Neoplasms / pathology. Myocardial Infarction / pathology. Myocardium / pathology. Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18761275.001).
  • [ISSN] 1532-6551
  • [Journal-full-title] Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
  • [ISO-abbreviation] J Nucl Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


39. Gawrychowski J, Bruliński K, Malinowski E, Papla B: Prognosis and survival after radical resection of primary adenosquamous lung carcinoma. Eur J Cardiothorac Surg; 2005 Apr;27(4):686-92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis and survival after radical resection of primary adenosquamous lung carcinoma.
  • OBJECTIVE: In order to evaluate the follow-up study of surgical treatment for primary adenosquamous lung carcinoma (ASC) we specified prognostic criteria, also in comparison with primary adenocarcinoma (AC).
  • CONCLUSIONS: Our findings indicate that in patients after radical operation for ASC, predominance for one of the histopathological components (adenous or squamous) within primary tumor is attended by worst prognosis.
  • Our study confirmed also that the prognosis of ASC of the lung was poorer than that of primary AC.
  • [MeSH-major] Carcinoma, Adenosquamous / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Cause of Death. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15784375.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Mallakin A, Sugiyama T, Taneja P, Matise LA, Frazier DP, Choudhary M, Hawkins GA, D'Agostino RB Jr, Willingham MC, Inoue K: Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell; 2007 Oct;12(4):381-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer.
  • Dmp1 (Dmtf1) is activated by oncogenic Ras-Raf signaling and induces cell-cycle arrest in an Arf, p53-dependent fashion.
  • The survival of K-ras(LA) mice was shortened by approximately 15 weeks in both Dmp1(+/-) and Dmp1(-/-) backgrounds, the lung tumors of which showed significantly decreased frequency of p53 mutations compared to Dmp1(+/+).
  • Approximately 40% of K-ras(LA) lung tumors from Dmp1(+/+) mice lost one allele of the Dmp1 gene, suggesting the primary involvement of Dmp1 in K-ras-induced tumorigenesis.
  • Loss of heterozygosity (LOH) of the hDMP1 gene was detectable in approximately 35% of human lung carcinomas, which was found in mutually exclusive fashion with LOH of INK4a/ARF or that of P53.
  • Thus, DMP1 is a pivotal tumor suppressor for both human and murine lung cancers.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2001 Nov 15;15(22):2934-9 [11711428.001]
  • [Cites] Genes Dev. 2001 Nov 15;15(22):2917-21 [11711426.001]
  • [Cites] Annu Rev Physiol. 2002;64:681-708 [11826285.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2204-19 [11884607.001]
  • [Cites] Clin Chest Med. 2002 Mar;23(1):65-81, viii [11901921.001]
  • [Cites] Curr Opin Genet Dev. 2003 Feb;13(1):77-83 [12573439.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):229-39 [12619108.001]
  • [Cites] Thorax. 2003 Oct;58(10):892-900 [14514947.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):42750-60 [12917399.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15930-5 [14665695.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):19-27 [14734447.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Lancet. 1992 Jan 18;339(8786):139-43 [1346009.001]
  • [Cites] Mol Cell Biol. 1996 Nov;16(11):6457-67 [8887674.001]
  • [Cites] Oncogene. 1996 Oct 17;13(8):1815-8 [8895529.001]
  • [Cites] Nature. 1997 May 15;387(6630):296-9 [9153395.001]
  • [Cites] Nature. 1997 May 15;387(6630):299-303 [9153396.001]
  • [Cites] Mol Cell Biol. 1998 Mar;18(3):1590-600 [9488476.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):5001-14 [9724636.001]
  • [Cites] J Biol Chem. 1998 Oct 30;273(44):29188-94 [9786929.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 14;1378(2):F115-77 [9823374.001]
  • [Cites] Nature. 1999 Jan 14;397(6715):164-8 [9923679.001]
  • [Cites] Gene. 1999 Mar 18;229(1-2):223-8 [10095122.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3993-8 [10097151.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2217-22 [10232611.001]
  • [Cites] Genes Dev. 1999 Sep 1;13(17):2207-17 [10485844.001]
  • [Cites] Gene. 2004 Sep 29;340(1):53-9 [15556294.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(1):220-32 [15601844.001]
  • [Cites] Nature. 2005 Jan 20;433(7023):278-85 [15662416.001]
  • [Cites] Genes Dev. 2005 Mar 15;19(6):643-64 [15769940.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2031-45 [16150895.001]
  • [Cites] Am J Hematol. 2005 Dec;80(4):282-7 [16315255.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):958-62 [16831050.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):663-73 [16915296.001]
  • [Cites] Cell. 2006 Oct 20;127(2):265-75 [17055429.001]
  • [Cites] Oncogene. 2006 Dec 14;25(59):7703-13 [16878159.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4329-35 [17237816.001]
  • [Cites] Oncogene. 2007 Nov 22;26(53):7457-66 [17546045.001]
  • [Cites] Oncogene. 1999 Nov 11;18(47):6605-14 [10597265.001]
  • [Cites] Genes Dev. 2000 Jul 15;14(14):1797-809 [10898794.001]
  • [Cites] Nat Genet. 2000 Nov;26(3):291-9 [11062467.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 4):3-13 [11479891.001]
  • [Cites] Prostate. 2001 Sep 15;48(4):248-53 [11536304.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):83-6 [11544530.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Oct;2(10):731-7 [11584300.001]
  • [Cites] Oncology. 2001;61 Suppl 1:3-13 [11598409.001]
  • [Cites] Eur J Cancer. 2001 Dec;37(18):2470-4 [11720845.001]
  • (PMID = 17936562.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106314-02; United States / NCI NIH HHS / CA / T32 CA079448; United States / NCI NIH HHS / CA / CA106314-03; United States / NCI NIH HHS / CA / R01 CA106314-01; United States / NCI NIH HHS / CA / CA106314-04; United States / NCI NIH HHS / CA / CA106314-02; United States / NCI NIH HHS / CA / R01 CA106314-03; United States / NCI NIH HHS / CA / R01 CA106314; United States / NCI NIH HHS / CA / CA106314-01; United States / NCI NIH HHS / CA / 5R01CA106314; United States / NCI NIH HHS / CA / R01 CA106314-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DMTF1 protein, human; 0 / Dmtf1 protein, mouse; 0 / TP53 protein, human; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS32754; NLM/ PMC2239345
  •  go-up   go-down


41. Ma K, Wang TY, He BL, Chang D, Gong M: [Impact of different mediastinal lymphadenectomy on clinical-stage IA non-small cell lung cancer]. Zhonghua Wai Ke Za Zhi; 2008 May 1;46(9):670-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of different mediastinal lymphadenectomy on clinical-stage IA non-small cell lung cancer].
  • OBJECTIVE: To study the role of different lymphadenectomy in the treatment of selected clinical-stage IA non-small cell lung cancer.
  • METHODS: All 115 postoperative patients admitted from January 1997 to May 2002 with pathologic-stage T1 who had been preoperatively diagnosed as clinical-stage I A non-small cell lung cancer were divided into a radical systematic mediastinal lymphadenectomy (LA) group and a mediastinal lymph node sampling (LS) group.
  • No statistically significant difference existed in modification of N staging, OS and DFS between LA group and LS group.
  • However, for patients with lesions of a diameter more than 2 cm, 5-year OS in LA group was significantly higher than that in LS groups (LA vs. LS = 78.2% vs. 54.5% ,P < 0.05), also 5-year DFS was significantly higher (LA vs. LS = 75.1% vs. 51.3%, P < 0.05).
  • In addition, patients with large cell carcinoma and adenosquamous carcinoma were associated with significantly poor 5-year OS (P < 0.05) , and patients with lymph node metastases were associated with poor 5-year OS as well as 5-year DFS (P < 0.01).
  • CONCLUSIONS: After being intraoperatively identified as T1 stage, patients with lesions of more than 2 cm in clinical-stage IA non-small cell lung cancer should be performed with LA to get a better survival, and patients with lesions of 2 cm or less should be performed with LS to decrease invasion.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Lymph Node Excision / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956719.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


42. Manxhuka-Kerliu S, Telaku S, Ahmetaj H, Baruti A, Loxha S, Kerliu A: Colorectal cancer: prognostic values. Bosn J Basic Med Sci; 2009 Feb;9(1):19-24
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal cancer: prognostic values.
  • After lung cancer colorectal cancer (Cc) is ranked the second, as a cause of cancer-related death.
  • There were investigated 149 cases of resection specimen with colorectal cancer, which were fixed in buffered neutral formalin and embedded in paraffin.
  • Adenocarcinoma was the most frequent histological type found in 85,90% of cases, in 60,94% of males and 39,06% of females; squamous cell carcinoma in 7,38%, in 63,63% of males and 36,36% of females; mucinous carcinoma in 4,68%, in 57,15% of males and 42,85% of females; while adenosquamous carcinoma, undifferentiated carcinoma and carcinoma in situ in 0,71% of cases each.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19284390.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


43. Suzuki C, Daigo Y, Ishikawa N, Kato T, Hayama S, Ito T, Tsuchiya E, Nakamura Y: ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res; 2005 Dec 15;65(24):11314-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway.
  • Gene expression profile analysis of non-small cell lung cancers (NSCLC) and subsequent functional analyses revealed that human ANLN, a homologue of anillin, an actin-binding protein in Drosophila, was transactivated in lung cancer cells and seemed to play a significant role in pulmonary carcinogenesis.
  • Immunohistochemical staining of nuclear ANLN on lung cancer tissue microarrays was associated with the poor survival of NSCLC patients, indicating that this molecule might serve as a prognostic indicator.
  • Our data imply that up-regulation of ANLN is a common feature of the carcinogenetic process in lung tissue, and suggests that selective suppression of ANLN could be a promising approach for developing a new strategy to treat lung cancers.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Contractile Proteins / metabolism. Lung Neoplasms / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. rhoA GTP-Binding Protein / metabolism
  • [MeSH-minor] Actins / metabolism. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Blotting, Western. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Movement. Enzyme Activation. Female. Flow Cytometry. Humans. Lung / metabolism. Lung / pathology. Male. Middle Aged. Prognosis. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Survival Rate. Tissue Array Analysis. Tumor Cells, Cultured. Wound Healing

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357138.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Contractile Proteins; 0 / RNA, Small Interfering; 0 / anillin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


44. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, Kristiansen G: Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res; 2008 Nov 15;14(22):7430-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer.
  • PURPOSE: In carcinomas, invasive tumor growth is accompanied by desmoplastic stroma reaction and facilitated by epithelial-mesenchymal transition (EMT) of cancer cells.
  • We investigated the prognostic significance of the EMT indicator proteins periostin and vimentin in comparison with versican, a putative indicator of the opposite mechanism mesenchymal-epithelial transition (MET), and to the desmoplasia proteins collagen and elastin in non-small cell lung cancer (NSCLC).
  • RESULTS: Of the 533 patients, 48% had squamous cell carcinoma, 47% adenocarcinoma, and 5% adenosquamous carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / metabolism. Cell Adhesion Molecules / biosynthesis. Lung Neoplasms / metabolism. Vimentin / biosynthesis
  • [MeSH-minor] Age Factors. Aged. Cell Differentiation / physiology. Collagen / biosynthesis. Elastin / biosynthesis. Epithelial Cells / metabolism. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Mesoderm / metabolism. Middle Aged. Prognosis. Sex Factors. Tissue Array Analysis. Versicans / biosynthesis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010860.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / Vimentin; 126968-45-4 / Versicans; 9007-34-5 / Collagen; 9007-58-3 / Elastin
  •  go-up   go-down


45. Lee HS, Kim MS, Lee JM, Kim SK, Kang KW, Zo JI: Intrathoracic gastric emptying of solid food after esophagectomy for esophageal cancer. Ann Thorac Surg; 2005 Aug;80(2):443-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathoracic gastric emptying of solid food after esophagectomy for esophageal cancer.
  • BACKGROUND: Information on the function of the intrathoracic stomach after esophageal resection for esophageal cancer is limited.
  • METHODS: Between February 2003 and August 2003, intrathoracic gastric emptying of solid food was evaluated by radioisotope in 56 of the patients who underwent esophageal replacement surgery with the stomach for esophageal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Gastric Emptying
  • [MeSH-minor] Carcinoma, Adenosquamous / surgery. Female. Food. Humans. Male. Middle Aged. Stomach / physiology. Stomach / surgery. Thoracic Cavity

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2005 Aug;80(2):447-8 [16039183.001]
  • (PMID = 16039182.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


46. Okamoto T, Maruyama R, Suemitsu R, Aoki Y, Wataya H, Kojo M, Ichinose Y: Prognostic value of the histological subtype in completely resected non-small cell lung cancer. Interact Cardiovasc Thorac Surg; 2006 Aug;5(4):362-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of the histological subtype in completely resected non-small cell lung cancer.
  • Non-small cell lung cancer (NSCLC), which includes several different histological subtypes, is usually treated by the same strategy.
  • However, the biological behavior of each cell type appears to be different.
  • We retrospectively reviewed the clinical records of 1119 consecutive NSCLC patients who underwent a complete resection, in order to investigate whether a histological cell type is a powerful prognostic factor.
  • The overall 5- and 10-year survivals of the patients with adenocarcinoma (AD), squamous cell carcinoma (SQ), large cell carcinoma (LA), and adenosquamous cell carcinoma (AS) were 54.2 and 40.2%, 51.6 and 30.3%, 40.9 and 18.7%, and 35.1 and 30.1%, respectively.
  • The AD patients had a significantly better survival than the non-AD patients in Stage I (P=0.0004), whereas the SQ patients had a better survival than the non-SQ patients in Stage II (P=0.018).
  • A multivariate survival analysis indicated the AD patients to have a significantly better survival than the SQ patients in Stage IA (P=0.04), while the SQ patients had a better survival than the AD patients in Stage II (P=0.03).
  • These above observations suggest that the prognosis after complete resection is different between adenocarcinoma and squamous cell carcinoma in Stage IA and II.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17670594.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


47. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C, BO17704 Study Group: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol; 2010 Sep;21(9):1804-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).
  • BACKGROUND: Bevacizumab, the anti-vascular endothelial growth factor agent, provides clinical benefit when combined with platinum-based chemotherapy in first-line advanced non-small-cell lung cancer.
  • CONCLUSIONS: Final analysis of AVAiL confirms the efficacy of bevacizumab when combined with cisplatin-gemcitabine.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Placebos. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] Cancer Cell. 2008 Sep 9;14(3):263-73 [18772115.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1227-34 [19188680.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3909-17 [14581415.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):391-400 [15136787.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4593-9 [9377574.001]
  • [Cites] Lung Cancer. 2005 Jan;47(1):69-80 [15603856.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7889-96 [16204015.001]
  • (PMID = 20150572.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00806923
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Placebos; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ PMC2924992
  •  go-up   go-down


48. Rea F, Marulli G, Schiavon M, Zuin A, Hamad AM, Rizzardi G, Perissinotto E, Sartori F: A quarter of a century experience with sleeve lobectomy for non-small cell lung cancer. Eur J Cardiothorac Surg; 2008 Sep;34(3):488-92; discussion 492
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A quarter of a century experience with sleeve lobectomy for non-small cell lung cancer.
  • OBJECTIVE: Sleeve lobectomy represents an effective and widely accepted surgical therapy for non-small cell lung carcinoma (NSCLC).
  • Pathology revealed 167 (83.9%) squamous carcinomas, 23 (11.6%) adenocarcinomas, 7 (3.5%) large cell and 2 (1%) adenosquamous carcinomas.
  • This emphasises the importance of a learning curve and encourages the performance of this procedure in experienced centres.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pulmonary Artery / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18579399.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


49. Liao QH: [A clinicopathological study of 16 autopsy cases of anthracosilicosis with lung cancer]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2005 Oct;23(5):340-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinicopathological study of 16 autopsy cases of anthracosilicosis with lung cancer].
  • OBJECTIVE: To investigate the clinicopathological characteristics of anthracosilicosis complicated with lung cancer.
  • METHODS: Tissue specimens from 16 autopsy cases of 0(+) anthracosilicosis complicated with lung cancer were retrospectively studied by hematoxylin-eosin, histochemical, and immunohistochemical staining.
  • The pneumoconiosis and dust fibrosis of different degrees in the lung were found.
  • Among 16 cases of lung cancer, there were 5 cases of squamous cell carcinoma, and 5 cases of small cell undifferentiated carcinoma, 3 cases of bronchioloalveolar carcinoma, 2 cases of adenocarcinoma and 1 case of adenosquamous carcinoma.
  • The typical pathological changes of anthracosilicosis complicated with lung cancer were: the cancer tissue was located at the side of coal dust fibrous focus and fibrosis lesion, or mixte with silicotic lesion.
  • CONCLUSIONS: The occurrence of some lung cancer may be related with fibrosis.
  • The dust-exposed workers can suffer from lung cancer which is histologically identical to the general lung tumor.
  • PCNA and Ki67 may be a prognostic index for anthracosilicosis with lung cancer, while vimentin may be a marker for the examination of dust fibrosis in anthracosilicosis.
  • [MeSH-major] Anthracosilicosis / pathology. Lung / pathology. Lung Neoplasms / pathology


50. Kawano R, Hino H, Hoshino T, Yokota T, Ikeda S, Hata E: [Primary lung cancer protruding into right main bronchus, successfully treated with endoscopic neodymium yttrium aluminum garnet (Nd-YAG) laser]. Kyobu Geka; 2009 Aug;62(9):807-11
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lung cancer protruding into right main bronchus, successfully treated with endoscopic neodymium yttrium aluminum garnet (Nd-YAG) laser].
  • A 67-year-old male patient with a chief complaint of cough and sputum had a primary lung cancer (squamous cell carcinoma) in the upper lobe of the right lung.
  • When preoperative lung cancer patient has an obstructive pneumonia causing by the protruding tumor into the central airway, a patency treatment of bronchial airway using endoscopic Nd-YAG laser may lead to decrease a perioperative risk.
  • [MeSH-major] Bronchi / pathology. Bronchoscopy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Laser Therapy / methods. Lung Neoplasms / pathology. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670784.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


51. Iwasaki A, Shirakusa T, Miyoshi T, Hamada T, Enatsu S, Maekawa S, Hiratsuka M: Prognostic significance of subcarinal station in non-small cell lung cancer with T1-3 N2 disease. Thorac Cardiovasc Surg; 2006 Feb;54(1):42-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of subcarinal station in non-small cell lung cancer with T1-3 N2 disease.
  • BACKGROUND: Surgical resection may continue to offer the best chance of long-term survival for patients with non-small cell lung cancer (NSCLC).
  • METHODS: We retrospectively reviewed 142 non-small cell lung cancer patients with T1-3 N2 in whom a curative approach had been attempted between January 1994 and December 2003.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Analysis of Variance. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Pulmonary Surgical Procedures. Retrospective Studies. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome


52. Kaneda M, Tarukawa T, Watanabe F, Adachi K, Sakai T, Nakabayashi H: Clinical features of primary lung cancer adjoining pulmonary bulla. Interact Cardiovasc Thorac Surg; 2010 Jun;10(6):940-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of primary lung cancer adjoining pulmonary bulla.
  • A few investigators have suggested a possible association between lung cancer and a pulmonary bulla.
  • Five hundred and forty-five cases with primary lung cancer were studied retrospectively by re-evaluation of their chest computed tomography (CT)-scans.
  • Cancer adjoined a bulla in 19 cases.
  • Bulla/cancer incidence was 3.5%.
  • In comparison with the control group, a ratio of squamous cell carcinoma (SCC) and large cell carcinoma was significantly high (P<0.05) and differentiation of the carcinoma was poor (P<0.001).
  • Although the pathological staging and lung function data revealed no statistical difference, the survival curve of bulla/cancer group was significantly worse (P<0.01).
  • Primary lung cancer adjoining pulmonary bulla tends to be poor in prognosis, even if it was small in size.
  • [MeSH-major] Blister / diagnosis. Carcinoma / diagnosis. Lung / pathology. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Large Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cell Differentiation. Humans. Incidence. Japan / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Respiratory Function Tests. Retrospective Studies. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20299444.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


53. Koshimune R, Aoe M, Toyooka S, Hara F, Ouchida M, Tokumo M, Sano Y, Date H, Shimizu N: Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. BMC Cancer; 2007;7:8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
  • Recently, YM529 as well as other third-generation BPs have also been shown to exert anti-tumor effects against various types of cancer cells both in vitro or/and in vivo.
  • In this study, we investigate the anti-tumor effect of YM529 on non-small cell lung cancer (NSCLC).
  • METHODS: Direct anti-tumor effect of YM529 against 8 NSCLC cell lines (adenocarcinoma: H23, H1299, NCI-H1819, NCI-H2009, H44, A549, adenosquamous cell carcinoma: NCI-H125, squamous cell carcinoma: NCI-H157) were measured by MTS assay and calculated inhibition concentration 50 % (IC50) values.
  • RESULTS: We found that there was direct anti-tumor effect of YM529 on 8 NSCLC cell lines in a dose-dependent manner and their IC50 values were 2.1 to 7.9 microM and YM529 induced apoptosis and G1 arrest cell cycle with dose-dependent manner and YM529 caused down regulation of phospholyration of ERK1/2 in signaling pathways of NSCLC cell line (NCI-H1819).
  • CONCLUSION: Our study demonstrate that YM529 showed direct anti-tumor effect on NSCLC cell lines in vitro, which supports the possibility that third-generation BPs including YM529 can be one of therapeutic options for NSCLC.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Non-Small-Cell Lung / drug therapy. Diphosphonates / pharmacology. Imidazoles / pharmacology. Lung Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Humans

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Enzymol. 1987;152:180-3 [3657568.001]
  • [Cites] Oral Oncol. 2004 Jan;40(1):43-51 [14662414.001]
  • [Cites] J Clin Invest. 1991 Dec;88(6):2095-105 [1661297.001]
  • [Cites] Curr Opin Genet Dev. 1997 Feb;7(1):75-9 [9024640.001]
  • [Cites] Br J Haematol. 1997 Sep;98(3):665-72 [9332325.001]
  • [Cites] Scand J Rheumatol. 1998;27(1):38-41 [9506876.001]
  • [Cites] Leukemia. 1998 Feb;12(2):220-9 [9519785.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5294-7 [9850051.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Feb 16;255(2):491-4 [10049736.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4919-26 [10519405.001]
  • [Cites] Lung Cancer. 2005 Jan;47(1):31-9 [15603852.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):853-9 [15701876.001]
  • [Cites] Leuk Res. 2005 Apr;29(4):451-7 [15725480.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2713-9 [15814653.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer Lett. 2006 Jul 8;238(1):111-8 [16112430.001]
  • [Cites] Clin Exp Metastasis. 2006;23(1):19-31 [16715352.001]
  • [Cites] J Bone Miner Res. 1999 Dec;14(12):2048-56 [10620064.001]
  • [Cites] Arch Biochem Biophys. 2000 Jan 1;373(1):231-41 [10620343.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1459-68 [10780527.001]
  • [Cites] Leukemia. 2000 May;14(5):841-4 [10803515.001]
  • [Cites] J Bone Miner Res. 2000 Nov;15(11):2211-21 [11092402.001]
  • [Cites] Leuk Res. 2001 Jan;25(1):77-83 [11137564.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Feb;296(2):235-42 [11160603.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2602-8 [11289137.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1126-34 [11308265.001]
  • [Cites] Bone. 2001 Oct;29(4):336-43 [11595616.001]
  • [Cites] J Med Chem. 2002 Aug 15;45(17):3721-38 [12166945.001]
  • [Cites] J Clin Pharmacol. 2002 Nov;42(11):1228-36 [12412821.001]
  • [Cites] J Cell Physiol. 2003 Apr;195(1):139-50 [12599217.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1971-8 [12799645.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9268-72 [3057505.001]
  • (PMID = 17222343.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; 0 / Imidazoles; 127657-42-5 / YM 529
  • [Other-IDs] NLM/ PMC1781945
  •  go-up   go-down


54. Sakurai H, Asamura H, Goya T, Eguchi K, Nakanishi Y, Sawabata N, Okumura M, Miyaoka E, Fujii Y, Japanese Joint Committee for Lung Cancer Registration: Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study. J Thorac Oncol; 2010 Oct;5(10):1594-601
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study.
  • INTRODUCTION: Women with non-small cell lung cancer (NSCLC) are more likely to have better survival than men.
  • METHODS: In 2005, the Japanese Joint Committee for Lung Cancer Registration performed a nationwide retrospective registry study regarding the prognosis and clinicopathologic profiles of patients who underwent resection for primary lung neoplasms in 1999.
  • Women had a higher incidence of adenocarcinoma (p < 0.001) and stage IA disease (p < 0.001) than men.
  • According to histology, the overall survival of women was significantly better than that of men for both adenocarcinoma (5-YSR, 77.7 versus 61.9%, p = 0.0000) and nonadenocarcinoma (5-YSR, 59.3 versus 53.1%, p = 0.035).
  • In adenocarcinoma, women had a significantly better prognosis than men for pathologic stage I/II disease.
  • CONCLUSIONS: Women with NSCLC, especially with an adenocarcinoma histology, had better survival than men.
  • Women were more likely to have adenocarcinoma and stage IA disease, which might account for the better prognosis in women.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / mortality. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Squamous Cell / mortality. Lung Neoplasms / mortality

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736855.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Kim HK, Choi YS, Kim K, Shim YM, Jeong SY, Lee KS, Kwon OJ, Kim J: Management of ground-glass opacity lesions detected in patients with otherwise operable non-small cell lung cancer. J Thorac Oncol; 2009 Oct;4(10):1242-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of ground-glass opacity lesions detected in patients with otherwise operable non-small cell lung cancer.
  • INTRODUCTION: When pure ground-glass opacity (GGO) lesions are detected in patients with otherwise operable non-small cell lung cancer, it is controversial whether to resect them simultaneously with the primary tumor or not.
  • METHODS: We retrospectively reviewed radiologic features and pathologic diagnoses of pure GGO lesions detected in otherwise operable non-small cell lung cancer.
  • CONCLUSIONS: When a pure GGO is detected in otherwise operable lung cancer, it should be resected to rule out the possibility of malignancy if the size is greater than 8 mm.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / surgery. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adult. Aged. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiography, Interventional. Retrospective Studies. Sensitivity and Specificity. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687762.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


56. Cadieux C, Kedinger V, Yao L, Vadnais C, Drossos M, Paquet M, Nepveu A: Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types. Cancer Res; 2009 Sep 15;69(18):7188-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The p75 and p110 isoforms of the CUX1 homeodomain protein are overexpressed in breast tumors and cancer cell lines.
  • We report that mammary tumors developed after a long latency period, and although various histopathologies were observed, the proportion of adenosquamous carcinomas was significantly higher in p75 CUX1 than in p110 CUX1 transgenic mice.
  • Metastasis to the lung was observed in three p75 CUX1 transgenic mice.
  • Interestingly, higher expression of erbB2 mRNA was seen in most tumors, not only solid carcinomas but also adenosquamous carcinomas, whereas higher expression of various Wnt genes and activation of the beta-catenin pathway was observed primarily in adenosquamous carcinomas.
  • Together, these results support the notion that oncogenic activity of CUX1 can facilitate the establishment of a Wnt/beta-catenin autocrine loop.
  • [MeSH-minor] Animals. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Caseins / biosynthesis. Caseins / genetics. Female. Humans. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Mammary Tumor Virus, Mouse / genetics. Mice. Mice, Transgenic. Protein Isoforms. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism. Transgenes. Wnt Proteins / metabolism

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19738070.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CUX1 protein, human; 0 / Caseins; 0 / Homeodomain Proteins; 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Wnt Proteins; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


57. Ak I, Sivrikoz MC, Entok E, Vardareli E: Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography. Eur J Cardiothorac Surg; 2010 Apr;37(4):792-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
  • The objective of our study was to compare the sensibility of the 2-deoxy-2-[18F] fluoro-d-glucose positron emission tomography/computed tomography (F-18 FDG PET/CT) for the detection of bone metastasis in patients with non-small-cell lung cancer (NSCLC) whose technetium 99m methylenediphosphonate (Tc-99m MDP) bone scans were absolutely normal.
  • RESULTS: Nine patients had squamous cell carcinoma, six had adenocarcinoma, three had large cell carcinoma and one had adenosquamous cell carcinoma.
  • Assessment of glucose metabolism with FDG PET/CT can represent a more powerful tool to detect early bone metastases in lung cancer than with traditional bone scans.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20015657.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


58. Sholl LM, John Iafrate A, Chou YP, Wu MT, Goan YG, Su L, Huang YT, Christiani DC, Chirieac LR: Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol; 2007 Oct;20(10):1028-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma.
  • Epidermal growth factor receptor (EGFR) gene copy number correlates with response to tyrosine kinase inhibitors in patients with nonsmall cell lung carcinoma.
  • Fluorescence in situ hybridization (FISH), a standard methodology to detect EGFR copy number abnormalities in nonsmall cell lung carcinoma, is limited by instrumentation and cost.
  • Chromogenic in situ hybridization (CISH) is an emerging alternative detection technique using light microscopy, but its utility in assessing EGFR copy number in lung cancer is not established.
  • To address the utility of CISH, we studied paraffin-embedded nonsmall cell lung carcinoma specimens from 77 Taiwanese nonsmoking women treated by surgery alone.
  • We recorded the number of signals per tumor cell nucleus, correlated EGFR copy number by CISH with FISH results, and used receiver operating characteristics to identify cut-off points for the CISH results.
  • Tumors were classified as adenocarcinoma (n=28), mixed adenocarcinoma with bronchioloalveolar features (n=25), bronchioloalveolar carcinoma (n=2), squamous cell carcinoma (n=15), and adenosquamous carcinoma (n=7).
  • CISH is an alternative assay to FISH in determining EGFR copy number status that may contribute to stratification of patients with nonsmall cell lung carcinoma for clinical trials and identify a subset of patients that should be treated with tyrosine kinase inhibitors.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Gene Dosage. Genes, erbB-1. In Situ Hybridization / methods. Lung Neoplasms / genetics. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Chromogenic Compounds / chemistry. Discriminant Analysis. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence / methods. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673923.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA074386; United States / NCI NIH HHS / CA / CA092824; United States / NCI NIH HHS / CA / CA90578
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogenic Compounds; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


59. Kim Y, Liu XS, Liu C, Smith DE, Russell RM, Wang XD: Induction of pulmonary neoplasia in the smoke-exposed ferret by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): a model for human lung cancer. Cancer Lett; 2006 Mar 28;234(2):209-19
Hazardous Substances Data Bank. 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of pulmonary neoplasia in the smoke-exposed ferret by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): a model for human lung cancer.
  • Research into dietary chemoprevention against lung carcinogenesis has been limited by the lack of appropriate animal models that closely mimic smoking-related human lung cancer.
  • Ferrets (Mustela putorius furo) have been used to study the biologic activities of carotenoids against smoke-induced lung lesions, but this model has yet to be thoroughly established and validated.
  • To determine the appropriateness of the ferret as a model for human lung cancer, we have performed a 6-month in vivo study in ferrets exposed to both tobacco smoke and a carcinogen (4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone, NNK) found in cigarette smoke.
  • Results showed that six out 12 ferrets exposed to both NNK injection and cigarette smoke developed grossly identifiable lung tumors whereas none of nine ferrets from the sham treatment group developed any lung lesions.
  • The histopathological types of these tumors (squamous cell carcinoma, adenosquamous carcinoma and adenocarcinoma) in ferret lungs are very similar to those in humans.
  • In addition, 10 out of 12 ferrets exposed to both NNK and cigarette smoke developed preneoplastic lesions (squamous metaplasia, dysplasia, and atypical adenomatous hyperplasia) with complex growth patterns whereas the sham group did not show any of these lesions.
  • In summary, the development of both preneoplastic lesions and gross lung tumors in ferrets provides an excellent and unique model for studying lung cancer chemoprevention with agents such as carotenoids, and for studying the molecular mechanism of carcinogenesis in the earlier stages of smoke-related lung cancer.
  • [MeSH-major] Carcinogens / toxicity. Disease Models, Animal. Ferrets. Lung Neoplasms / etiology. Nitrosamines / toxicity. Smoking / adverse effects
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Animals. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Humans. Immunohistochemistry. Male. Precancerous Conditions / etiology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894421.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / T32 DK062032
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosamines; 64091-91-4 / 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone
  •  go-up   go-down


60. Liu HH, Jauregui M, Zhang X, Wang X, Dong L, Mohan R: Beam angle optimization and reduction for intensity-modulated radiation therapy of non-small-cell lung cancers. Int J Radiat Oncol Biol Phys; 2006 Jun 1;65(2):561-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beam angle optimization and reduction for intensity-modulated radiation therapy of non-small-cell lung cancers.
  • PURPOSE: To optimize beam angles and reduce the number of beams used for intensity-modulated radiation therapy (IMRT) of non-small-cell lung cancer (NSCLC).
  • RESULTS: Each anatomic structure, e.g., tumor or lung, had its own preferred beam angles.
  • CONCLUSIONS: Use of fewer beams (e.g., five) for lung IMRT could result in acceptable plan quality but improved treatment efficiency.
  • [MeSH-major] Algorithms. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radiotherapy. Humans. Technology, Radiologic / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690438.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 74043
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T: Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol; 2009 Jan;4(1):5-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
  • For lung cancer, MET gene amplification is reported to occur in a subset of adenocarcinomas.
  • Although somatic mutations of MET in lung adenocarcinomas are rare, all but one of those reported so far entail a splice mutation deleting the juxtamembrane domain for binding the c-Cbl E3-ligase; normally such binding leads to ubiquitination and receptor degradation, and loss of this domain leads to MET activation.
  • The purpose of this study was to clarify in the role of MET activation in lung carcinogenesis.
  • MATERIALS AND METHODS: MET gene copy number was determined by real-time quantitative polymerase chain reaction in 187 of the patients with lung cancer and the MET gene splice mutation deleting the juxtamembrane domain was examined by direct sequencing in 262.
  • [MeSH-major] Alternative Splicing. Gene Amplification. Lung Neoplasms / genetics. Mutation / genetics. Proto-Oncogene Proteins / genetics. Receptors, Growth Factor / genetics. Small Cell Lung Carcinoma / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Base Sequence. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Gene Dosage. Humans. Male. Middle Aged. Molecular Sequence Data. Neoplasm Staging. Pneumonectomy. Prognosis. Protein Structure, Tertiary. Proto-Oncogene Proteins c-cbl / metabolism. Proto-Oncogene Proteins c-met. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics. Sequence Deletion. Tumor Cells, Cultured. Ubiquitin-Protein Ligases / metabolism. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096300.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.6.5.2 / ras Proteins; EC 6.3.2.- / Proto-Oncogene Proteins c-cbl; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


62. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, Nukiwa T, Miyaoka E, Japanese Joint Committee of Lung Cancer Registry: A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol; 2008 Jan;3(1):46-52
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers.
  • PURPOSE: The validation of tumor, node, metastasis staging system in terms of prognosis is an indispensable part of establishing a better staging system in lung cancer.
  • METHODS: In 2005, 387 Japanese institutions submitted information regarding the prognosis and clinicopathologic profiles of patients who underwent pulmonary resections for primary lung neoplasms in 1999 to the Japanese Joint Committee of Lung Cancer Registry.
  • The data of 13,010 patients with only lung carcinoma histology (97.6%) were analyzed in terms of prognosis and clinicopathologic characteristics.
  • For the small cell histology (n = 390), the 5-year survival rates according to clinical (c) and pathologic (p) stages were as follows: 58.8% (n = 161) and 58.3% (n = 127) for IA, 58.0% (n = 77) and 60.2% (n = 79) for IB, 47.1% (n = 17) and 40.6% (n = 29) for IIA, 25.3% (n = 38) and 41.1% (n = 29) for IIB, 29.0% (n = 61) and 28.3% (n = 60) for IIIA, 36.3% (n = 19) and 34.6% (n = 40) for IIIB, and 27.8% (n = 12) and 30.8% for IV (n = 13).
  • For the non-small cell histology (n = 12,620), the 5-year survival rates according to c-stage and p-stage were as follows: 77.3% (n = 5642) and 83.9% (n = 4772) for IA, 59.8% (n = 3081) and 66.3% (n = 2629) for IB, 54.1% (n = 205) and 61.0% (n = 361) for IIA, 43.9% (n = 1227) and 47.4% (n = 1330) for IIB, 38.3% (n = 1628) and 32.8% (n = 1862) for IIIA, 32.6% (n = 526) and 29.6% (n = 1108) for IIIB, and 26.5% (n = 198) and 23.1% (n = 375) for IV.
  • Adenocarcinoma, female gender, and age less than 50 years were significant favorable prognostic factors.
  • CONCLUSION: This large registry study provides benchmark prognostic statistics for lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Registries
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Aged. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Hospitals, Teaching. Humans. Japan. Male. Middle Aged. Models, Biological. Neoplasm Staging. Prognosis. Reproducibility of Results. Retrospective Studies. Surveys and Questionnaires. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166840.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Qin BM, Chen X, Zhu JD, Pei DQ: Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Res; 2005 Mar;15(3):212-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy.
  • Lung cancer is one of the leading causes of death with one of the lowest survival rates.
  • However, a subset of lung cancer patients who are of Asian origin and carry somatic mutations in epidermal growth factor receptor or EGFR have responded remarkable well to two tyrosine kinase inhibitors, gefitinib and erlotinib.
  • In this report, we identified ten somatic mutations from a total of 41 lung cancer patients in China.
  • These results suggest that a large portion of Chinese adenocarcinoma patients could benefit from gefitinib or erlotinib.
  • [MeSH-major] Lung Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adult. Amino Acid Sequence. Carcinoma, Adenosquamous / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. China. Exons. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Mutation. Protein Structure, Tertiary. Receptor, Epidermal Growth Factor / genetics. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780185.001).
  • [ISSN] 1001-0602
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


64. Jin X, Zhang J, Gao Y, Ding K, Wang N, Zhou D, Jen J, Cheng S: Relationship between mitochondrial DNA mutations and clinical characteristics in human lung cancer. Mitochondrion; 2007 Sep;7(5):347-53
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between mitochondrial DNA mutations and clinical characteristics in human lung cancer.
  • However, roles of mutations and polymorphisms in some diseases are among heated debate, especially for cancer.
  • To investigate the possible role of mtDNA mutations in lung cancer, we sequenced complete mtDNA of lung cancer tissues, corresponding normal (i.e., non-cancerous) lung tissues, and peripheral blood samples from 55 lung cancer patients and examined the relationship between mtDNA mutations or polymorphisms and clinical parameters.
  • There was no association of incidence of specific mtDNA mutation or polymorphism with patients' gender, age at diagnosis, smoking history, tumor type or tumor stage (P>0.05).
  • This study revealed a variety of mtDNA mutations and mtDNA polymorphisms in human lung cancer, some of which might be involved in human lung carcinogenesis.
  • [MeSH-major] DNA, Mitochondrial / genetics. Lung Neoplasms / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adenocarcinoma / genetics. Aged. Carcinoma, Adenosquamous / genetics. Carcinoma, Small Cell / genetics. Carcinoma, Squamous Cell / genetics. Female. Humans. Male. Middle Aged. Point Mutation

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707697.001).
  • [ISSN] 1567-7249
  • [Journal-full-title] Mitochondrion
  • [ISO-abbreviation] Mitochondrion
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


65. Kikuchi S, Yamada D, Fukami T, Maruyama T, Ito A, Asamura H, Matsuno Y, Onizuka M, Murakami Y: Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma. Cancer; 2006 Apr 15;106(8):1751-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.
  • BACKGROUND: The tumor suppressor gene TSLC1/IGSF4 on chromosomal region 11q23 is frequently inactivated by promoter methylation in various cancers, including nonsmall cell lung carcinoma (NSCLC).
  • Methylation was observed in all histologic subtypes of NSCLC, including adenocarcinoma (29 of 68, 43%), squamous cell carcinoma (14 of 26, 54%), adenosquamous carcinoma (1 of 2, 50%), and large cell carcinoma (1 of 7, 14%).
  • The TSLC1/IGSF4 methylation was also significantly associated with a shorter disease-free survival (P = .049), providing an independent prognostic factor (P = .038) in adenocarcinoma patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. DNA Methylation. Genes, Tumor Suppressor. Immunoglobulins / genetics. Lung Neoplasms / genetics. Membrane Proteins / genetics. Promoter Regions, Genetic. Smoking / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Aged. Cell Adhesion Molecules. CpG Islands / genetics. Disease-Free Survival. Female. Humans. Male. Polymorphism, Single-Stranded Conformational. Prognosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16534787.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CADM1 protein, human; 0 / Cell Adhesion Molecules; 0 / Immunoglobulins; 0 / Membrane Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


66. Sun Y, Lin H, Zhu Y, Feng J, Chen Z, Li G, Zhang X, Zhang Z, Tang J, Shi M, Hao X, Han H: [A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi; 2006 Jun 20;9(3):254-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients].
  • The aim of this study is to observe the clinical anticancer effect of Rg3 in combination with chemotherapy regimen NP (vinorelbine+cisplatin) in advanced non-small cell lung cancer (NSCLC).
  • Types of pathology: adenocarcinoma, 71; squamous cell carcinoma, 29; adenosquamous carcinoma, 8; others, 7.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21172156.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


67. Martin RC, Li Y, Liu Q, Barker DF, Doll MA, Hein DW: Manganese superoxide dismutase expression as a function of genotype and lung cancer pathology. Cancer Invest; 2010 Oct;28(8):813-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Manganese superoxide dismutase expression as a function of genotype and lung cancer pathology.
  • METHODS: One hundred lung cancer specimens and matched normal lung parenchyma from the same patient were evaluated for MnSOD expression.
  • CONCLUSION: MnSOD expression is significantly reduced in lung adenocarcinoma and squamous cell carcinoma compared to the matched normal lung tissue.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Mol Med. 2001 Jan;7(1):13-9 [11115602.001]
  • [Cites] DNA Cell Biol. 2009 Jan;28(1):3-7 [18821846.001]
  • [Cites] Free Radic Biol Med. 2002 Oct 15;33(8):1047-60 [12374616.001]
  • [Cites] Pharmacogenetics. 2003 Oct;13(10):607-18 [14515059.001]
  • [Cites] Am J Clin Pathol. 2004 Sep;122(3):395-404 [15362370.001]
  • [Cites] J Biol Chem. 1969 Nov 25;244(22):6049-55 [5389100.001]
  • [Cites] J Biol Chem. 1973 Jul 10;248(13):4793-6 [4578091.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7634-8 [6961438.001]
  • [Cites] J Theor Biol. 1984 Feb 7;106(3):403-22 [6717035.001]
  • [Cites] Science. 1985 Jan 25;227(4685):375-81 [2981433.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] BMC Genet. 2004 Dec 14;5:33 [15598343.001]
  • [Cites] J Surg Res. 2005 Mar;124(1):92-7 [15734485.001]
  • [Cites] Cancer Lett. 2005 Sep 28;227(2):133-9 [16112416.001]
  • [Cites] Arch Surg. 2005 Dec;140(12):1204-9; discussion 1209 [16365243.001]
  • [Cites] Eur Respir J. 2007 Feb;29(2):273-8 [17005588.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5176-82 [17785574.001]
  • [Cites] Lung Cancer. 2008 May;60(2):277-84 [18061304.001]
  • [Cites] Ann Surg Oncol. 2009 Feb;16(2):515-23 [19018598.001]
  • [Cites] Lung Cancer. 2002 Aug;37(2):143-6 [12140136.001]
  • (PMID = 20690800.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA034627-23; United States / NCI NIH HHS / CA / R01 CA034627; United States / NCI NIH HHS / CA / R01 CA034627-23; United States / NCI NIH HHS / CA / R01-CA034627
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.15.1.1 / Superoxide Dismutase
  • [Other-IDs] NLM/ NIHMS321748; NLM/ PMC3196322
  •  go-up   go-down


68. Pöttgen C, Eberhardt W, Grannass A, Korfee S, Stüben G, Teschler H, Stamatis G, Wagner H, Passlick B, Petersen V, Budach V, Wilhelm H, Wanke I, Hirche H, Wilke HJ, Stuschke M: Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol; 2007 Nov 1;25(31):4987-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial.
  • PURPOSE: To investigate the role of prophylactic cranial irradiation (PCI) within a trimodality protocol (chemotherapy, chemoradiotherapy, surgery) for patients with operable stage IIIA non-small-cell lung cancer (NSCLC).
  • One hundred six patients were eligible (arm A: 51, arm B: 55), 90 males and 16 females, 50 with squamous cell, 16 with large cell, five with adenosquamous, and 35 with adenocarcenoma (median age, 57 years; range, 37 to 71 years).
  • [MeSH-major] Brain Neoplasms / prevention & control. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Germany. Humans. Male. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17971598.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


69. Spizzo G, Seeber A, Mitterer M: Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis. Anticancer Res; 2009 Dec;29(12):5245-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: No data on the tolerability and effects of pamidronate in non-small cell lung cancer patients with bone metastasis are available.
  • CONCLUSION: The diagnosis of bone metastasis and the consequent routine administration of pamidronate have an impact on survival of NSCLC patients; this drug is a good candidate for routine use in haemato-oncological centres.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy. Diphosphonates / therapeutic use. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20044644.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; OYY3447OMC / pamidronate
  •  go-up   go-down


70. Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, Kuyama S, Segawa Y, Kamei H, Umemura S, Bessho A, Tabata M, Tanimoto M, Okayama Lung Cancer Study Group: A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol; 2010 Jan;5(1):99-104
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
  • BACKGROUNDS: Efficacy of gefitinib therapy strongly depends on epidermal growth factor receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer.
  • Two other patients developed interstitial lung disease (grades 1 and 2).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Mutation / genetics. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Erlotinib Hydrochloride. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898258.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


71. Gharagozloo F, Margolis M, Tempesta B, Strother E, Najam F: Robot-assisted lobectomy for early-stage lung cancer: report of 100 consecutive cases. Ann Thorac Surg; 2009 Aug;88(2):380-4
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robot-assisted lobectomy for early-stage lung cancer: report of 100 consecutive cases.
  • METHODS: Over a 54-month period, 100 consecutive patients with stage I and II (T1 or T2N0, and T1 or T2N1) lung cancer (42 men, 58 women; mean age 65 +/- 8 years) underwent robotic VATS lobectomy.
  • Tumor type was adenocarcinoma (57), squamous cell carcinoma (25), 7 adenosquamous carcinoma (7), bronchoalveolar (3), large cell (1), poorly differentiated (3), carcinoid (2), mucoepidermoid (1), spindle cell (1).
  • At a median follow-up of 32 months (range, 1 to 59), 1 patient (1%) died of his cancer, 6 (6%) had distant metastases, and 2 (2%) had a second lung primary cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Robotics / methods. Thoracic Surgery, Video-Assisted / methods
  • [MeSH-minor] Aged. Carcinoma, Adenosquamous / surgery. Feasibility Studies. Female. Humans. Length of Stay. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / epidemiology. Retrospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2009 Aug;88(2):384 [19632378.001]
  • (PMID = 19632377.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


72. Carvalho L: Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. Rev Port Pneumol; 2009 Nov-Dec;15(6):1101-19
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry.
  • The current state of molecular knowledge on lung cancer demands a histological classification which goes beyond small-cell and non-small-cell carcinoma to provide support for tailored therapy in aiding in understanding of the drugs currently available.
  • As diagnosis and follow-up in the vast majority of lung cancer cases is based on biopsies and cytology samples, Immunohistochemical Bronchial Pulmonary Carcinoma Classification (IBPCC) is necessary to reveal the raft of characteristics available.
  • The immunohistochemical panel clarifies the main morphology and cytology characteristics to maintain the leading histological types as squamous cell carcinoma (high weight molecular cytokeratins/HWMC), adenosquamous carcinoma (CK7, TTF1, HWMA), neuroendocrine carcinoma (Chrg, Syn, CD56, TTF1, Ki67), adenocarcinoma (CK7, CK20, TTF1) and bring the polymorphic and pleomorphic carcinomas under a single banner of pleomorphic carcinoma (Ck7, TTF1, HWMC, VMT, Desmin, Actin) which shelters large cell carcinomas and sarcomatoid carcinomas.
  • Lung cancer chemotherapy will still be based on platinum and gemcitabine for the near future and the IBPCC is a simple and efficient tool for streamlining the registration of lung cancer histological characteristics in biopsies and other reduced samples to support clinical evidence and trials.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Bronchial Neoplasms / classification. Bronchial Neoplasms / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859629.001).
  • [ISSN] 2172-6825
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Portugal
  • [Number-of-references] 80
  •  go-up   go-down


73. Xu JB, Bao Y, Liu X, Liu Y, Huang S, Wang JC: Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small cell lung carcinoma. Lung Cancer; 2007 Oct;58(1):36-43
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small cell lung carcinoma.
  • Large cell carcinoma (LCC) of the lung is defined as an undifferentiated carcinoma without the characteristic features of squamous cell (SqC), small cell, or adenocarcinomas (AdC).
  • In the present study, the expression level of the important tumor suppressor, transforming growth factor beta type II receptor (TGFBR2), was examined both in LCC and non-LCC tumors, which include AdC, SqC and adenosquamous carcinoma (Ad-SqC).
  • Immunohistochemical staining with TGFBR2 antibody revealed statistically significant or near significant differences in the reduced expression in LCC (80% of cases) versus AdC (42.1% of cases, P=0.0288) and SqC (47.1% of cases, P=0.0589), or LCC versus non-LCC (45% of cases, P=0.02).
  • The differences in the expression level of TGFBR2 between LCC and non-LCC were consistent with the histopathologic classification of these tumors, suggesting that the defective TGFBR2 expression might contribute to the carcinogenesis and/or development of LCC.
  • [MeSH-major] Carcinoma, Large Cell / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Protein-Serine-Threonine Kinases / biosynthesis. Receptors, Transforming Growth Factor beta / biosynthesis
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Biomarkers, Tumor. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Male. Middle Aged. Mutation. Neoplasm Staging

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17566598.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Transforming Growth Factor beta; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


74. Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P: Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol; 2009 Jan;4(1):12-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
  • BACKGROUND: Progression of non-small cell lung cancer (NSCLC) from early- to late-stage may signify the accumulation of gene mutations.
  • Mutation detection of multiple genes is limited by the low amount of deoxyribonucleic acid extracted from low-volume diagnostic lung biopsies.
  • Their low-volume lung biopsies underwent WGA before direct sequencing for epidermal growth factor receptor (EGFR), KRAS (rat sarcoma virus), p53, and CMET (mesenchymal-epithelial transition factor) mutations.
  • RESULTS: It is feasible for low-volume lung biopsies to undergo WGA for mutational analysis.
  • WGA may be used to expand starting deoxyribonucleic acid from low-volume lung biopsies for further analysis of advanced-stage NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Mutation / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-met / genetics. Receptor, Epidermal Growth Factor / genetics. Tumor Suppressor Protein p53 / genetics. ras Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Base Sequence. Biopsy. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. DNA, Neoplasm / genetics. Feasibility Studies. Female. Gene Amplification. Humans. Male. Middle Aged. Molecular Sequence Data. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. Sensitivity and Specificity. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096301.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


75. Mori T, Nomori H, Ikeda K, Kawanaka K, Shiraishi S, Katahira K, Yamashita Y: Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol; 2008 Apr;3(4):358-64
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FDG uptake of each lesion was quantitatively measured by a contrast ratio of standard uptake value (SUV-CR) between the lesions and contralateral lung.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Lung Neoplasms / diagnosis. Positron-Emission Tomography / methods. Solitary Pulmonary Nodule / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Diagnostic Imaging. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Prognosis. Prospective Studies. ROC Curve. Sensitivity and Specificity. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379353.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


76. Piantedosi FV, Caputo F, Mazzarella G, Gilli M, Pontillo A, D'Agostino D, Campbell S, Marsico SA, Bianco A: Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study. Cancer Chemother Pharmacol; 2008 Apr;61(5):803-7
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
  • To investigate the activity/toxicity of T 175 mg/m2 on day 1, I 3 g/m2 on day 1 (with Mesna uroprotection) and G 1,000 mg/m2 on day 1-8, every 3 weeks in the treatment of advanced/metastatic NSCLC, 46 patients (38 male, 8 female) with NSCLC were enrolled: mean age 58 (range 33-70); Stage IIIB/IV=15/31; ECOG PS 0-1/2=31/15; HISTOLOGY: adenocarcinoma=20, squamous=14, large cell=3, NSCLC=8, adenosquamous=1.
  • Additional non-haematological toxicities were mild nausea, emesis and fatigue.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639396.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


77. McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, Haber DA, Sharma SV, Settleman J: Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res; 2009 May 1;69(9):3937-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
  • Using a high-throughput cancer cell line screening platform, we found that only 2 of 637 tested human tumor-derived cell lines show significant sensitivity to single-agent sunitinib exposure.
  • These two cell lines [a non-small-cell lung cancer (NSCLC) and a rhabdomyosarcoma] showed expression of highly phosphorylated PDGFRA.
  • In the sunitinib-sensitive adenosquamous NSCLC cell line, PDGFRA expression was associated with focal PFGRA gene amplification, which was similarly detected in a small fraction of squamous cell NSCLC primary tumor specimens.
  • Moreover, in this NSCLC cell line, focal amplification of the gene encoding the PDGFR ligand PDGFC was also detected, and silencing PDGFRA or PDGFC expression by RNA interference inhibited proliferation.
  • A similar codependency on PDGFRA and PDGFC was observed in the sunitinib-sensitive rhabdomyosarcoma cell line.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2008 May 15;112(10):2119-29 [18338812.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3389-95 [18451166.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2442-9 [18458038.001]
  • [Cites] Mod Pathol. 2000 Jun;13(6):632-7 [10874667.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6093-101 [11156522.001]
  • [Cites] Oncogene. 2001 Feb 1;20(5):626-33 [11313995.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):143-52 [11544480.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):327-37 [12538485.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Cell. 1984 Nov;39(1):89-97 [6091919.001]
  • [Cites] Cell. 1986 Jul 18;46(2):155-69 [3013421.001]
  • [Cites] Cell. 1993 Apr 23;73(2):321-34 [7682895.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5357-64 [15928335.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2316-21 [16461907.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):524-8 [17049587.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):254-8 [17262795.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41 [18077425.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] Hum Pathol. 2008 Feb;39(2):184-93 [17950782.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):650-6 [18235126.001]
  • [Cites] Genes Dev. 2008 May 15;22(10):1276-312 [18483217.001]
  • (PMID = 19366796.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / P50 CA090578-060008; United States / NCI NIH HHS / CA / CA115830-04; United States / NCI NIH HHS / CA / P20 CA090578-06; United States / NCI NIH HHS / CA / R01 CA115830-04; United States / NCI NIH HHS / CA / CA090578-060008
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Indoles; 0 / Ligands; 0 / Lymphokines; 0 / Platelet-Derived Growth Factor; 0 / Pyrroles; 0 / RNA, Small Interfering; 0 / platelet-derived growth factor C; 0 / sunitinib; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Other-IDs] NLM/ NIHMS98241; NLM/ PMC2676215
  •  go-up   go-down


78. Picozzi G, Paci E, Lopez Pegna A, Bartolucci M, Roselli G, De Francisci A, Gabrielli S, Masi A, Villari N, Mascalchi M: Screening of lung cancer with low dose spiral CT: results of a three year pilot study and design of the randomised controlled trial ''Italung-CT''. Radiol Med; 2005 Jan-Feb;109(1-2):17-26
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening of lung cancer with low dose spiral CT: results of a three year pilot study and design of the randomised controlled trial ''Italung-CT''.
  • PURPOSE: To report the results of a three-year observational pilot study of lung cancer screening with low dose computed tomography (CT) and to present the study design of a randomised clinical trial named as ''Italung-CT''.
  • Indeterminate nodules were managed according to the recommendations of the Early Lung Cancer Action Project.
  • One (1.6%) prevalent lung cancer (adenosquamous carcinoma) and one (2.2%) incident lung cancer (small cell cancer at the first annual examination) were observed, as well as a pulmonary localisation of Hodgkin's lymphoma (at the second annual test).
  • In addition, one subject underwent lung surgery for a chondromatous hamartoma.
  • [MeSH-major] Lung Neoplasms / radiography. Tomography, Spiral Computed
  • [MeSH-minor] Female. Humans. Lung / radiography. Male. Middle Aged. Pilot Projects. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15729183.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


79. Voltolini L, Rapicetta C, Luzzi L, Ghiribelli C, Ligabue T, Paladini P, Gotti G: Lung cancer with chest wall involvement: predictive factors of long-term survival after surgical resection. Lung Cancer; 2006 Jun;52(3):359-64
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer with chest wall involvement: predictive factors of long-term survival after surgical resection.
  • Multimodal management of lung cancer extending to chest wall and type of surgical procedure to be performed are still debated.
  • The aim of this retrospective analysis was to analyze the predictive factors of long-term survival after surgery, focusing on depth of infiltration, type of surgical intervention and possible role of preoperative therapies, comparing survival of these patients with that of a group of patients affected by a Pancoast tumour and surgical treated in the same period.
  • Histology revealed adenocarcinoma in 23 cases, squamous cell carcinoma in 34, large cells anaplastic carcinoma in 8, adenosquamous carcinoma in 3.
  • An extrapleural dissection was performed in 48 patients while combined pulmonary and chest wall en bloc resection was required in 20 patients.
  • Histological type was adenocarcinoma in 10 cases, squamous cell carcinoma in 4 and adenosquamous carcinoma in 1.
  • A univariate analysis performed in the CW group showed that survival was significantly affected by nodal status, stage, extension of chest wall invasion, type of lung resection and residual disease.
  • [MeSH-major] Carcinoma / mortality. Lung Neoplasms / mortality. Thoracic Wall
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Thoracic Surgical Procedures / mortality

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644062.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


80. Okami J, Higashiyama M, Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Miyaoka E, Japanese Joint Committee of Lung Cancer Registry: Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: prognostic factors for overall survival and risk factors for postoperative complications. J Thorac Oncol; 2009 Oct;4(10):1247-53
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: prognostic factors for overall survival and risk factors for postoperative complications.
  • INTRODUCTION: This retrospective study was designed to identify the predictors of long-term survival and the risk factors for complications after surgery in patients aged 80 years or older with clinical (c)-stage I non-small cell lung cancer.
  • METHODS: The Japanese Joint Committee of Lung Cancer Registry collated the clinicopathological profiles and outcomes of 13,344 patients who underwent pulmonary resection for primary lung cancer in 1999.
  • The data of 367 patients aged 80 years or older with c-stage I non-small cell lung cancer were analyzed for prognostic factors and risk factors for postoperative complications.
  • CONCLUSIONS: Octogenarian patients with c-stage I lung cancer in this study had a satisfactory long-term outcome and low-mortality rate.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Comorbidity. Female. Humans. Lymph Node Excision. Male. Mediastinum / surgery. Neoplasm Staging. Postoperative Complications. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609223.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Massard G, Ducrocq X, Kochetkova EA, Porhanov VA, Riquet M: Sampling or node dissection for intraoperative staging of lung cancer: a multicentric cross-sectional study. Eur J Cardiothorac Surg; 2006 Jul;30(1):164-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sampling or node dissection for intraoperative staging of lung cancer: a multicentric cross-sectional study.
  • OBJECTIVE: This study compares accuracy of sampling versus formal node dissection in patients with primary lung cancer.
  • PATIENTS AND METHODS: During a 4-month period, 208 consecutive patients (172 men, 36 women) without bulky disease underwent resection for primary lung cancer in three centers.
  • There were 108 squamous cell carcinomas, 621 adenocarcinomas, 18 bronchoalveolar carcinomas, 8 large cell carcinomas, 4 adenosquamous carcinomas and 8 neuroendocrine carcinomas.
  • CONCLUSION: Radical mediastinal dissection is a mandatory adjunct to resection for lung cancer with curative attempt.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Lymph Node Excision / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2007 Jan;31(1):142-3; author reply 143-4 [17092737.001]
  • (PMID = 16725340.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


82. Yang HX, Hou X, Lin P, Rong TH, Yang H, Fu JH: [A prognostic analysis of N0-1M0 intralobar metastatic non-small cell lung cancer]. Zhonghua Yi Xue Za Zhi; 2009 Sep 22;89(35):2486-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A prognostic analysis of N0-1M0 intralobar metastatic non-small cell lung cancer].
  • OBJECTIVE: To assess whether it is reasonable to downgrade intralobar metastatic non-small cell lung cancer from T4 disease through a prognostic analysis of N0-1M0 disease.
  • METHODS: A retrospective analysis was conducted to assess the survival of patients with intralobar metastatic non-small cell lung cancer with pathological N0-1M0 disease.
  • The median survival was 24.0 months for patients with adenosquamous carcinoma; while for patients with other pathologic types, the median survival was 48 months.
  • Adenosquamous carcinoma had a shorter survival time than other pathologic types (P = 0.003).
  • The median survival time was 60.0 months for patients undergoing non-pneumonectomy resection and 24 months for patients undergoing pneumonectomy (P = 0.023).
  • CONCLUSION: It is reasonable to downgrade the T4 classification of non-small cell lung cancer with intralobar metastasis.
  • Adenosquamous carcinoma has a poor prognosis.
  • Further study of a larger sample size is warranted.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


83. Varlotto JM, Recht A, Nikolov M, Flickinger JC, Decamp MM: Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. Cancer; 2009 Feb 15;115(4):851-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer.
  • BACKGROUND: It is uncertain whether lymphadenectomy (LA) affects overall survival (OS) or disease-free survival (DFS) rates for patients with stage I nonsmall cell lung cancer (NSCLC), as is the optimal number of lymph nodes that should be recovered.
  • For patients diagnosed from 1998 to 2002 undergoing only N1 or only N2 dissections, LA was also associated with statistically significant improvements in OS in both groups and a significant difference and trend for improved DFS in the 2 groups, respectively.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Lymph Node Excision
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. SEER Program. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • (PMID = 19140203.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Zeng X, Wu SF, Zhou WX, Li DJ, Gao J, Liang ZY, Liu TH: [EGFR and HER2 gene expression status and their correlation in non-small cell lung cancer]. Zhonghua Bing Li Xue Za Zhi; 2006 Jul;35(7):398-402
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [EGFR and HER2 gene expression status and their correlation in non-small cell lung cancer].
  • OBJECTIVE: To explore epidermal growth factor receptor (EGFR) and HER2 gene status, to assess the correlation between EGFR and HER2 gene status, and to investigate the role of copy number increase and amplification of EGFR gene and HER2 gene in the tumorigenesis and disease progression of non-small-cell lung cancer.
  • METHODS: Using Path Vysion kit and LSI EGFR SpectrumOrange/CEP7 Spectrum Green probes, EGFR gene and HER2 gene status were evaluated by fluorescence insitu hybridization (FISH) using formalin-fixed, paraffin-embedded samples from 31 patients with non-small-cell lung cancer, including 20 adenocarcinomas, 2 squamous cell carcinomas, 2 large cell carcinoma, 4 bronchoalveolar carcinomas and 3 adenosquamous carcinomas.
  • Of 25 cases without EGFR gene non-amplification, four tetrasomy and 5 polysomy were detected.
  • CONCLUSIONS: EGFR or HER2 copy number increase is much more frequent than gene amplification in no-small-cell lung cancer.
  • Both genes are involved in the tumorigenesis and development of lung cancer.
  • EGFR/HER2 dimer is one of the predominant heterodimerization types in lung cancer.
  • The interactions between EGFR and HER2 may play a rule in the progression of non-small-cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Genes, erbB-1 / genetics. Genes, erbB-2 / genetics. Lung Neoplasms / pathology


85. Chang YL, Wu CT, Lee YC: Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. J Thorac Cardiovasc Surg; 2007 Sep;134(3):630-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients.
  • OBJECTIVES: According to our previous study, the concurrent detection of p53 and epidermal growth factor receptor mutations significantly improves the clonality assessment and impact management of patients with multiple primary lung cancer.
  • METHODS: A database of 1651 patients was evaluated for unilateral and bilateral synchronous multiple primary lung cancers.
  • RESULTS: The 5-year survival for all synchronous multiple primary lung cancers was 35.3%.
  • Notably, lymph node metastasis, extranodal extension, vascular invasion, tumors with adenosquamous carcinoma or different histology, and poor survival were observed.
  • CONCLUSION: An aggressive surgical approach is safe and justified in patients with synchronous multiple primary lung cancers and node-negative diseases.
  • The status of this particular form of non-small cell lung cancers might be considered in the conventional TNM staging system for more accurate prediction of patient prognosis.
  • [MeSH-major] Lung Neoplasms / surgery. Neoplasms, Multiple Primary / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Cardiovasc Surg. 2008 Aug;136(2):542
  • (PMID = 17723810.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


86. Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, Squire JA, Gout PW, Lam S, Wang YZ: Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res; 2006 Jul 1;12(13):4043-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes.
  • PURPOSE: Lung cancer is a biologically diverse disease and relevant models reflecting its diversity would facilitate the improvement of existing therapies.
  • With a view to establishing such models, we developed and evaluated xenografts of a variety of human lung cancers.
  • EXPERIMENTAL DESIGN: Using nonobese diabetic/severe combined immunodeficiency mice, subrenal capsule xenografts were generated from primary lung cancer tissue, including moderately and poorly differentiated squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, large cell undifferentiated carcinoma, and carcinosarcoma.
  • Four transplantable lines were developed from rapidly growing tumors (>5 generations), i.e., a small cell lung carcinoma, large cell undifferentiated carcinoma, pulmonary carcinosarcoma, and squamous cell carcinoma.
  • Analyses including spectral karyotyping, comparative genomic hybridization, and fluorescence in situ hybridization, revealed that the xenografts were genetically similar to the original tumors, showing chromosomal abnormalities consistent with karyotypic changes reported for lung cancer.
  • CONCLUSIONS: The subrenal capsule xenograft approach essentially provides a living tumor bank derived from patient material and a means for isolating and expanding specific cell populations.
  • The transplantable tumor lines seem to provide good models for studying various aspects of tumor progression and a platform for developing novel therapeutic regimens, with the possibility of patient-tailored therapies.
  • [MeSH-major] Cell Line, Tumor. Disease Models, Animal. Lung Neoplasms / pathology. Subrenal Capsule Assay


87. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD: A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med; 2006 Dec;3(12):e486
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
  • However, DNA methylation markers that are highly specific and sensitive for common tumors would be useful for the early detection of cancer, and those required for the malignant phenotype would identify pathways important as therapeutic targets.
  • METHODS AND FINDINGS: In an effort to identify new cancer-specific methylation markers, we employed a high-throughput global expression profiling approach in lung cancer cells.
  • We identified 132 genes that have 5' CpG islands, are induced from undetectable levels by 5-aza-2'-deoxycytidine in multiple non-small cell lung cancer cell lines, and are expressed in immortalized human bronchial epithelial cells.
  • As expected, these genes were also expressed in normal lung, but often not in companion primary lung cancers.
  • Methylation analysis of a subset (45/132) of these promoter regions in primary lung cancer (n = 20) and adjacent nonmalignant tissue (n = 20) showed that 31 genes had acquired methylation in the tumors, but did not show methylation in normal lung or peripheral blood cells.
  • We studied the eight most frequently and specifically methylated genes from our lung cancer dataset in breast cancer (n = 37), colon cancer (n = 24), and prostate cancer (n = 24) along with counterpart nonmalignant tissues.
  • We found that seven loci were frequently methylated in both breast and lung cancers, with four showing extensive methylation in all four epithelial tumors.
  • CONCLUSIONS: By using a systematic biological screen we identified multiple genes that are methylated with high penetrance in primary lung, breast, colon, and prostate cancers.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1995 Jan 15;55(2):220-3 [7812947.001]
  • [Cites] Cancer. 1995 May 1;75(9):2400-1 [7712451.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4268-72 [7671234.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2116-28 [16489012.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] Cell. 2006 Apr 21;125(2):315-26 [16630819.001]
  • [Cites] Cancer Lett. 2007 Mar 8;247(1):56-71 [16644104.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:32-91 [8806092.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):564-9 [10749912.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):249-55 [11196170.001]
  • [Cites] Int J Cancer. 1998 Dec 9;78(6):766-74 [9833771.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):41-6 [10471496.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9027-34 [15604268.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):166-72 [15671542.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 16;97(4):273-82 [15713962.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3654-60 [15897561.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):275-85 [16226703.001]
  • [Cites] Int J Cancer. 2005 Dec 10;117(5):738-45 [15981206.001]
  • [Cites] Bioinformatics. 2005 Nov 1;21(21):4067-8 [16141249.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Nat Chem Biol. 2005 Sep;1(4):216-22 [16408038.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):653-8 [16423993.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Nat Genet. 2006 Feb;38(2):149-53 [16444255.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3105-9 [11306494.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • [Cites] Hum Mol Genet. 2001 Dec 15;10(26):3001-7 [11751682.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):514-9 [11839671.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4822-9 [12101420.001]
  • [Cites] Genet Epidemiol. 2002 Jun;23(1):70-86 [12112249.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Nat Genet. 2003 Mar;33 Suppl:245-54 [12610534.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1114-21 [12615730.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1596-601 [12670910.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:22-7 [12724209.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3735-42 [12839967.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3104-9 [15131050.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3465-73 [15150099.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Hum Mol Genet. 2004 Sep 1;13(17):1969-78 [15254011.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5982-7 [15342377.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):707-17 [15343277.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6410-5 [15374948.001]
  • [Cites] Oncogene. 2004 Oct 7;23(46):7669-78 [15361840.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Oncogene. 1992 Jan;7(1):171-80 [1311061.001]
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Jul;10(3):183-9 [7522041.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Cancer Res. 1995 Jan 1;55(1):28-30 [7805035.001]
  • [CommentIn] PLoS Med. 2006 Dec;3(12):e479 [17194184.001]
  • (PMID = 17194187.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE5816
  • [Grant] United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / U01 CA084971; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / U01CA84971
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCNA1 protein, human; 0 / Cyclin A; 0 / Cyclin A1; 0 / DNA-Binding Proteins; 0 / MSX1 Transcription Factor; 0 / MSX1 protein, human; 0 / Transcription Factors; 148814-46-4 / BNC1 protein, human; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC1716188
  •  go-up   go-down


88. DeArmond DT, Mahtabifard A, Fuller CB, McKenna RJ Jr: Photodynamic therapy followed by thoracoscopic sleeve lobectomy for locally advanced lung cancer. Ann Thorac Surg; 2008 May;85(5):e24-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy followed by thoracoscopic sleeve lobectomy for locally advanced lung cancer.
  • We present a case in which photodynamic therapy was used with curative intent to downsize an obstructing endobronchial non-small cell lung cancer in advance of resection via video-assisted thoracoscopic surgery with right upper lobe sleeve lobectomy.
  • [MeSH-major] Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Neoadjuvant Therapy. Photochemotherapy / methods. Pneumonectomy / methods. Thoracic Surgery, Video-Assisted / methods
  • [MeSH-minor] Bronchoscopy. Combined Modality Therapy. Debridement / methods. Female. Humans. Lung / pathology. Lymph Node Excision. Middle Aged. Neoplasm Staging. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18442525.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


89. Okudela K, Suzuki M, Kageyama S, Bunai T, Nagura K, Igarashi H, Takamochi K, Suzuki K, Yamada T, Niwa H, Ohashi R, Ogawa H, Mori H, Kitamura H, Kaneko T, Tsuneyoshi T, Sugimura H: PIK3CA mutation and amplification in human lung cancer. Pathol Int; 2007 Oct;57(10):664-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PIK3CA mutation and amplification in human lung cancer.
  • To explore the significance of phosphatidylinositol-3-kinase, catalytic, alpha (PIK3CA) in the carcinogenesis in human lung, mutations and copy number changes were investigated in 148 Japanese patients with primary cancer of the lung.
  • For biological validation, the effects of exogenously expressed wild-type and mutated PIK3CA were studied in an immortalized human airway epithelial cell line.
  • The prevalence of copy number gains was higher in men, smokers, and in patients with squamous cell carcinoma than in the opposite categories.
  • The present demonstrates an important role of PIK3CA in human lung carcinogenesis.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma / genetics. Lung Neoplasms / genetics. Mutation. Phosphatidylinositol 3-Kinases / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Line, Transformed. DNA, Neoplasm / analysis. Female. Gene Dosage. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathol Int. 2007 Nov;57(11):757
  • (PMID = 17803655.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human
  •  go-up   go-down


90. Dong QG, Han BH, Huang JS, Yang LM, Huang J, Zhao CY, Lu LQ: [Analysis of EGFR mutations in 176 cases of non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2006 Sep;28(9):686-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of EGFR mutations in 176 cases of non-small cell lung cancer].
  • OBJECTIVE: To analyze the incidence and profile of mutations in epidermal growth factor receptor (EGFR) in Chinese patients with non-small cell lung cancer (NSCLC).
  • METHODS: A total of 176 cases of NSCLC tissue was enrolled in this study, among which 123 normal lung samples were also included.
  • RESULTS: The EGFR gene in exon 19-21 was of wild type in all normal lung tissues detected.
  • Mutations were found in 57 cases of 176 lung cancer samples, with an incidence of 32. 4%.
  • The EGFR mutations were more frequent in female patients than male ones, in adenocarcinoma and adenosquamous cell carcinoma versus cancer of other histologies.
  • These mutations are more frequently detected in female, adenocarcinoma and adenosquamous cell carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adult. Aged. Amino Acid Sequence. Base Sequence. Carcinoma, Squamous Cell / genetics. Codon. DNA Mutational Analysis. Exons. Female. Gene Deletion. Humans. Male. Middle Aged. Mutation, Missense. Sex Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274376.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Codon; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


91. Gharagozloo F, Margolis M, Tempesta B: Robot-assisted thoracoscopic lobectomy for early-stage lung cancer. Ann Thorac Surg; 2008 Jun;85(6):1880-5; discussion 1885-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robot-assisted thoracoscopic lobectomy for early-stage lung cancer.
  • BACKGROUND: Video-assisted thoracic surgery lobectomy is an accepted oncologic procedure for patients with early-stage lung cancer.
  • We studied the use of the da Vinci surgical robot for mediastinal, hilar, and vascular dissection during video-assisted thoracic surgery lobectomy in patients with early-stage lung cancer.
  • METHODS: During a 41-month-period, 61 patients (27 men, 34 women; mean age, 68.2 years) underwent a robot-assisted video-assisted thoracic surgery lobectomy and complete mediastinal nodal dissection for early-stage lung cancer (stages I, II).
  • There were 34 adenocarcinoma, 14 squamous cell carcinoma, 6 adenosquamous, 1 large cell, 2 bronchoalveolar, 2 poorly differentiated cancers, and 2 carcinoid tumors.
  • CONCLUSIONS: Robot-assisted vascular and nodal dissection during video-assisted thoracic surgery lobectomy for early-stage lung cancer is feasible.
  • [MeSH-major] Lung Neoplasms / surgery. Pneumonectomy / instrumentation. Robotics / instrumentation. Thoracic Surgery, Video-Assisted / instrumentation

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18498788.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


92. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA: Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer; 2006 Jan 16;94(1):128-35
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.
  • Epithelial cell adhesion molecule (Ep-CAM; CD326) is used as a target by many immunotherapeutic approaches, but little data are available about Ep-CAM expression in major human malignancies with respect to level, frequency, tumour stage, grade, histologic tumour type and impact on survival.
  • We analysed by immunohistochemical staining tissue microarrays with 4046 primary human carcinoma samples from colon, stomach, prostate and lung cancers for both frequency and intensity of Ep-CAM expression under highly standardised conditions.
  • High-level Ep-CAM expression was observed in 97.7% (n=1186) of colon, 90.7% of gastric (n=473), and 87.2% of prostate cancers (n=414), and in 63.9% of lung cancers (n=1287).
  • No detectable Ep-CAM staining was found with only 0.4% of colon, 2.5% of gastric, 1.9% of prostate cancers, and 13.5% of lung cancers.
  • The only significant correlation of Ep-CAM expression with tumour grading was observed in colon cancer where high-level Ep-CAM expression on grade 3 tumours was down to 92.1% (P<0.0001).
  • Adenosquamous and squamous carcinomas of the lung had a lower percentage of high-level Ep-CAM expression compared to adenocarcinomas with 35.4 and 53.6%, respectively, and with 45.5 and 17.3% of tumours being Ep-CAM negative.
  • With the exception of moderately differentiated colon carcinoma, where patients not expressing Ep-CAM on their tumours showed an inferior survival (P=0.0014), correlation of Ep-CAM expression with survival did not reach statistical significance for any of the other cancer indications and subgroups.
  • This is because the most common human cancers show (i) a low frequency of Ep-CAM-negative tumours, (ii) a high frequency of Ep-CAM expression on cells of a given tumour, and (iii) for most cancers, an insignificant influence of tumour staging, grading and histology on Ep-CAM expression.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Cell Adhesion Molecules / biosynthesis. Colonic Neoplasms / genetics. Lung Neoplasms / genetics. Neoplasm Staging. Prostatic Neoplasms / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2001 Sep;195(1):72-9 [11568893.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):620-8 [11505407.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):883-8 [11948467.001]
  • [Cites] Cancer Gene Ther. 2002 Apr;9(4):382-9 [11960289.001]
  • [Cites] Int J Cancer. 2002 Jul 1;100(1):101-10 [12115595.001]
  • [Cites] Lancet. 2002 Aug 31;360(9334):671-7 [12241873.001]
  • [Cites] Cancer Immunol Immunother. 2003 Jul;52(7):429-37 [12695858.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2837-48 [12855664.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):764-72 [14566826.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4782-91 [14581349.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2139-48 [14633587.001]
  • [Cites] Vaccine. 2004 Jan 26;22(5-6):773-80 [14741172.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1095-103 [14983507.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2659-69 [15102668.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3131-6 [15131054.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5748-58 [15195135.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5818-24 [15313925.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5391-402 [15328177.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5464-71 [15328185.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):365-75 [15349812.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Mar;76(3):1438-42 [286328.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1231-5 [7059945.001]
  • [Cites] J Biol Response Mod. 1984;3(2):138-50 [6374043.001]
  • [Cites] Br J Cancer. 1987 Dec;56(6):714-21 [2449234.001]
  • [Cites] Hybridoma. 1990 Aug;9(4):377-87 [2210778.001]
  • [Cites] Cancer Immunol Immunother. 1999 Dec;48(9):517-24 [10602889.001]
  • [Cites] J Mol Med (Berl). 1999 Oct;77(10):699-712 [10606205.001]
  • [Cites] J Clin Pathol. 1999 Sep;52(9):701-4 [10655996.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):482-7 [10821496.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:254-61; discussion 261-2 [10911918.001]
  • [Cites] Lancet. 2000 Dec 9;356(9246):1981-2 [11130529.001]
  • [Cites] Clin Exp Immunol. 2001 Jan;123(1):9-14 [11167991.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):550-4 [11251980.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4105-11 [11358833.001]
  • [Cites] J Cell Biol. 1994 Apr;125(2):437-46 [8163559.001]
  • [Cites] Lancet. 1994 May 14;343(8907):1177-83 [7909866.001]
  • [Cites] Cancer Immunol Immunother. 1997 Mar;44(1):1-9 [9111578.001]
  • [Cites] J Cell Biol. 1997 Dec 1;139(5):1337-48 [9382878.001]
  • [Cites] J Cell Biol. 1998 Mar 23;140(6):1519-34 [9508783.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1319-23 [9563756.001]
  • [Cites] Gut. 1999 May;44(5):709-14 [10205210.001]
  • [Cites] Gene Ther. 1999 Aug;6(8):1469-74 [10467371.001]
  • [Cites] J Urol. 1999 Oct;162(4):1462-6 [10492238.001]
  • [Cites] Breast Cancer Res Treat. 2004 Aug;86(3):207-13 [15567937.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7555-65 [15569986.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8534-40 [15574759.001]
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):619-28 [15472903.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):83-8 [15613858.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):342-9 [15655555.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):3715-21 [15736402.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):882-7 [15756257.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2882-9 [15805290.001]
  • [Cites] Cancer Immunol Immunother. 2005 Jun;54(6):557-70 [15570423.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1767-72 [15870832.001]
  • [Cites] Onkologie. 2005 Jun;28(6-7):347-50 [15933423.001]
  • [Cites] Mol Immunol. 2006 Mar;43(8):1129-43 [16139892.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jul;55(7):785-96 [16187083.001]
  • [Cites] Oncogene. 2001 Oct 11;20(46):6679-88 [11709702.001]
  • (PMID = 16404366.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human
  • [Other-IDs] NLM/ PMC2361083
  •  go-up   go-down


93. Tatematsu A, Shimizu J, Murakami Y, Horio Y, Nakamura S, Hida T, Mitsudomi T, Yatabe Y: Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res; 2008 Oct 1;14(19):6092-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor mutations in small cell lung cancer.
  • PURPOSE: The vast majority of epidermal growth factor receptor (EGFR) mutations occur in lung adenocarcinoma, and even rare cases of other subtypes with this mutation, such as adenosquamous cell carcinoma, are associated with adenocarcinoma histology.
  • According to this adenocarcinoma-specific nature of EGFR mutation, analysis of EGFR mutations with small cell lung cancers (SCLC) may provide a clue to its histogenesis.
  • The patients were mainly in the light smoker and histologic combined subtype.
  • Notably, in three tumors of the combined SCLC subtype, both components of adenocarcinoma and SCLC harbored an EGFR mutation, whereas gene amplification was detected only in the adenocarcinoma component.
  • CONCLUSIONS: Although EGFR mutations are rare in SCLC, a combined subtype of SCLC with adenocarcinoma in light smokers may have a chance of harboring EGFR mutations.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genes, erbB-1. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / physiology. Small Cell Lung Carcinoma / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829487.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


94. Sanada H, Hayashi A, Tomimitsu S, Ikeda K, Nakanishi K, Hiyama J, Hidaka D, Sawamoto R, Miyagawa Y, Misumi Y, Fujii A, Nakatsubo S, Tsuru M, Omagari J, Koshizuka H: [Estimation of preoperative induction chemoradiotherapy effectiveness for non small-cell lung cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2012-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Estimation of preoperative induction chemoradiotherapy effectiveness for non small-cell lung cancer].
  • We have performed the clinical evaluations of preoperative induction chemoradiotherapy (CRTx) for 25 patients with non small-cell lung cancer (male: 19, female: 6, mean age: 66.4-year-old).
  • In the histological type of lung cancer, there were 12 patients of adenocarcinoma, 7 of squamous cell carcinoma, 1 of adenosquamous carcinoma, 1 of anaplastic carcinoma, and 4 of large cell carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Paclitaxel / administration & dosage. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037308.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


95. Kodama K, Okami J, Maeda J, Tokunaga T, Kanzaki R, Fujiwara A, Higashiyama M: [Complete resection of Pancoast tumor following induction chemoradiotherapy improves survival]. Kyobu Geka; 2010 Jan;63(1):9-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We retrospectively analyzed 23 patients with pT3-4, N0-3 Pancoast tumors who underwent combined chest wall resection including the 1st rib, and discuss the anatomical considerations, assessment of induction therapy, and surgical approaches for these cancers.
  • METHODS: Between 1983 and 2006, 23 patients with Pancoast tumors underwent combined resection of the 1st rib at our institute.
  • There were 10 each of squamous cell carcinoma and adenocarcinoma, 2 large cell carcinoma, and 1 adenosquamous carcinoma.
  • RESULTS: A posterior approach was employed in 14 patients, an anterior approach in 7, and a combined anterior and posterior approach in 2.
  • [MeSH-major] Lung Neoplasms / surgery. Pancoast Syndrome / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20077826.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


96. Cilli A, Ozkaynak C, Onur R, Erogullari I, Ogus C, Cubuk M, Arslan G, Ozdemir T: Lung cancer detection with low-dose spiral computed tomography in chronic obstructive pulmonary disease patients. Acta Radiol; 2007 May;48(4):405-11
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer detection with low-dose spiral computed tomography in chronic obstructive pulmonary disease patients.
  • PURPOSE: To determine whether low-dose spiral computed tomography (LDCT) can improve the lung cancer detection rate in chronic obstructive pulmonary disease (COPD) subjects.
  • MATERIAL AND METHODS: From October 1999 to December 2003, 374 COPD patients underwent LDCT for lung carcinoma screening.
  • RESULTS: On the baseline spiral CT scan, 132 of 374 patients (35.2%) had at least one non-calcified nodule that required periodic follow-up with CT scans.
  • Of the 374 COPD subjects, nine patients with primary lung cancer (2.4%) were detected: six were squamous cell carcinomas, two were small-cell lung carcinomas (SCLC), and one was adenosquamous carcinoma.
  • One subject with stage IA squamous cell carcinoma received radiotherapy, as pulmonary function was severely impaired.
  • CONCLUSION: LDCT increases early lung carcinoma detection rate in COPD patients, but pulmonary function impairment may reduce its benefit.
  • [MeSH-major] Carcinoma / radiography. Lung Neoplasms / radiography. Pulmonary Disease, Chronic Obstructive / complications. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Bronchoscopy. Calcinosis / radiography. Carcinoma, Adenosquamous / radiography. Carcinoma, Small Cell / radiography. Carcinoma, Squamous Cell / radiography. Female. Follow-Up Studies. Humans. Male. Mass Screening. Middle Aged. Neoplasm Staging. Pneumonectomy. Radiation Dosage. Solitary Pulmonary Nodule / radiography. Sputum / cytology. Thoracic Surgery, Video-Assisted


97. Ventsiavichius V, Tsitsenas S, Tikuĭshis R: [Potentialities of surgical treatment for concomitance of pulmonary tuberculosis and lung cancer]. Probl Tuberk Bolezn Legk; 2007;(5):32-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Potentialities of surgical treatment for concomitance of pulmonary tuberculosis and lung cancer].
  • The paper deals with the important problem of pulmonary surgery--the capacities of surgical treatment in concomitance of pulmonary tuberculosis and lung cancer.
  • In 1990 to 2002, the Santarishkes Republican Tuberculosis and Lung Diseases Hospital and the Department of Thoracic Surgery and Oncology, Vilnius University Cancer Institute operated on 2218 patients with lung cancer, of them 46 (2.1%) were diagnosed as having concomitance of lung cancer and tuberculosis.
  • The diagnosis of central and peripheral lung cancer was established in 37 (80.4%) and 9 (19.6%) patients, respectively.
  • Histology revealed squamous-cell tumors in 24 (52.2%) patients, adenocarcinoma in 10 (21.7%), and adenosquamous-cell carcinomas in 12 (26.1%) patients.
  • Surgery is the method of choice in the treatment of concomitance of pulmonary tuberculosis and lung cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / complications. Lung Neoplasms / surgery. Tuberculosis, Pulmonary / complications

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598460.001).
  • [ISSN] 1728-2993
  • [Journal-full-title] Problemy tuberkuleza i bolezneĭ legkikh
  • [ISO-abbreviation] Probl Tuberk Bolezn Legk
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


98. Togashi K, Koike T, Emura I, Usuda H: [Indication for limited surgery on small lung cancer tumors measuring 1cm or less in diameter on preoperative computed tomography and long-term results]. Kyobu Geka; 2008 Jul;61(7):519-22; discussion 522-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication for limited surgery on small lung cancer tumors measuring 1cm or less in diameter on preoperative computed tomography and long-term results].
  • OBJECTIVE: Non-invasive lung cancers showed a good prognosis after limited surgery.
  • But it is still uncertain about invasive lung cancers.
  • We investigated the indications for limited surgery for small lung cancer tumors measuring 1 cm or less in diameter on preoperative computed tomography (CT).
  • METHODS: This study retrospectively analyzed of 1,245 patients who underwent complete resection of lung cancer between 1989 and 2004 in our hospital.
  • RESULTS: All diseases were detected by medical checkup, 52 % of the patients were not definitively diagnosed with lung cancer before surgery.
  • Adenocarcinoma was histologically diagnosed in 49 patients (79%).
  • Other histologic types included squamous cell carcinoma (8), large cell carcinoma (1), small cell carcinoma (1), carcinoid (2), and adenosquamous cell carcinoma (1).
  • There were 3 deaths from cancer recurrence, while there were no deaths in 14 patients with bronchioloalveolar carcinoma CONCLUSION: After limited surgery, non-invasive cancer showed good long-term results, while invasive cancer showed a recurrence rate of 2.3% to 79% even though the tumor measured 1 cm or less in diameter on preoperative CT.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616092.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


99. Miyamoto T, Baba M, Sugane T, Nakajima M, Yashiro T, Kagei K, Hirasawa N, Sugawara T, Yamamoto N, Koto M, Ezawa H, Kadono K, Tsujii H, Mizoe JE, Yoshikawa K, Kandatsu S, Fujisawa T, Working Group for Lung Cancer: Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol; 2007 Oct;2(10):916-26
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week.
  • BACKGROUND: A phase I/II study was first conducted for the treatment of stage I non-small cell lung cancer (NSCLC) from 1994 to 1999 to determine the optimal dose.
  • The patients' 5-year lung cancer-specific survival rate was 68% (IA: 87%, IB: 42%).
  • No toxic reactions in the lung greater than grade 3 were detected.
  • [MeSH-major] Carbon Radioisotopes / therapeutic use. Carcinoma, Non-Small-Cell Lung / radiotherapy
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Large Cell / radiotherapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Dose Fractionation. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2007 Oct;2(10):887-8 [17909348.001]
  • (PMID = 17909354.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes
  •  go-up   go-down


100. Yaren A, Oztop I, Kargi A, Ulukus C, Onen A, Sanli A, Binicier O, Yilmaz U, Alakavuklar M: Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. Int J Clin Pract; 2006 Jun;60(6):675-82
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.
  • In non-small-cell lung cancer (NSCLC), stage of the disease is still the most important prognostic factor.
  • Other than stage, many biological markers and many other prognostic factors are studied to define their effects on prognosis of lung cancer.
  • In this study, we aimed to evaluate the expressions of Bax and bcl-2 genes which are important in apoptosis and c-kit, which is a tyrosine kinase transmembrane receptor, as well as searched their response to treatment modalities and effects on survival.
  • Sixty-nine NSCLC cases' pathological samples were stained with specific Bax, bcl-2 and c-kit dyes by immunohistochemical (IHC) methods.
  • Their histological subtypes were as follows: of 69 cases, 36 (52.2%) were squamous cell carcinoma, 28 (40.6%) were adenocarcinoma, five (7.2%) were adenosquamous cell carcinoma (two patients) and large-cell carcinoma (three patients).
  • The positive immunostaining rates for Bax and bcl-2 in whole group, squamous cell carcinoma and adenocarcinoma groups were 40.6%/36.2%, 55.6/69.4% and 25.0/0.0%, respectively.
  • The positive immune staining rates for c-kit in whole group, squamous cell carcinoma and adenocarcinoma groups were 7.2, 5.6 and 7.1%, respectively.
  • We didn't find any correlation with Bax, bcl-2 and c-kit expressions and clinicopathological parameters such as age, tumour size, lymph node involvement, smoking, stage of the disease, response to radiotherapy and chemotherapy.
  • C-kit expression was also found not related with survival in whole group whereas found as a bad prognostic factor in patients with squamous cell carcinoma.
  • These findings could indicate that the expression of apoptotic pathway markers and c-kit may have a role in the prognosis of early stage NSCLC, especially with squamous cell carcinoma subtype.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-kit / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16805752.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down






Advertisement